National Academies Press: OpenBook
« Previous: 8 Toward an Integrated Approach to Accelerating Research and Product Development for Rare Diseases
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

References

AAAS (American Association for the Advancement of Science). 2009. Programs, Science and Policy, R&D Budget and Policy Program. http://www.aaas.org/spp/rd/guitotal.htm (accessed September 3, 2010).

AAP (American Academy of Pediatrics) Medical Home Initiatives for Children with Special Needs Project Advisory Committee. 2002. The medical home. Pediatrics 110(1): 184-186.

Abernethy, A. P., G. Raman, E. M. Balk, J. M. Hammond, L. A. Orlando, J. L. Wheeler, J. Lau, and D. C. McCrory. 2009. Systematic review: reliability of compendia methods for off-label oncology indications. Annals of Internal Medicine 150(5):336-343.

AbioMed, Inc. 2005. ABIOMED Announces Increased Reimbursement from CMS for Successful Recovery of the Native Heart (press release). http://www.abiomed.com/news/CMS_Reimbursement.cfm (accessed August 10, 2010).

AbioMed, Inc. 2009. Form 10-Q. http://www.faqs.org/sec-filings/091106/ABIOMED-INC_10-Q/ (accessed August 10, 2010).

ACP (American College of Physicians). 2004. Patient-Centered, Physician-Guided Care for the Chronically Ill: The American College of Physicians Prescription for Change. Philadelphia, PA: American College of Physicians.

ACR (American College of Rheumatology). 2010. Summary of January 21 Teleconference with FDA Regarding Colchicine. http://www.rheumatology.org/advocacy/colchicine_fda.pdf (accessed August 10, 2010).

ACS (American Cancer Society). 2010. Clinical Trials: State Laws Regarding Insurance Coverage. http://www.cancer.org/docroot/ETO/content/ETO_6_2x_State_Laws_Regarding_Clinical_Trials.asp (accessed August 10, 2010).

Adams, J. U. 2008. Imprinting and genetic disease: Angelman, Prader-Willi, and Beckwith-Wiedemann syndromes. Nature Education 1(1). http://www.nature.com/scitable/topicpage/imprinting-and-genetic-disease-angelman-prader-willi-923 (accessed September 24, 2010).

AdvaMed (Advanced Medical Technology Association). 2004. Future Trends in Medical Device Innovation. http://www.advamed.org/MemberPortal/About/NewsRoom/MediaKits/futuretrendsinmedicaldeviceinnovaton.htm (accessed August 10, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

AdvaMed. 2009. Statement Presented by Susan Alpert to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. November 23.

Aetna. 2010. Clinical Policy Bulletin: Heart Transplantation. http://www.aetna.com/cpb/medical/data/500_599/0586.html (accessed August 10, 2010).

AIMBE (American Institute for Medical and Biological Engineering). 2005. AIMBE Hall of Fame salutes PET as one of 24 achievements in medical, biological engineering. Molecular Imaging News, March 10.

Aiuti, A., I. Brigida, F. Ferrua, B. Cappelli, R. Chiesa, S. Marktel, and M. Roncarolo. 2009. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. Immunologic Research 44(1-3):150-159.

Alliance for a Stronger FDA. 2009. Written Statement of the Alliance for a Stronger FDA, U.S. Food and Drug Administration Regarding FY2011 Appropriations for the U.S. Food and Drug Administration Submitted to the Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, U.S. Senate, March 26, 2010. http://fdaalliance.files.wordpress.com/2009/11/alliance-statement-senate-appropriations-committee-fy-11.doc (accessed August 10, 2010).

Anand, G. 2005. How drugs for rare diseases became lifeline for companies. Wall Street Journal, November 15. http://online.wsj.com/article/SB113202332063297223.html (accessed August 10, 2010).

Anderson, T. 2009. Novartis under fire for accepting new reward for old drug. Lancet 373(9673):1414. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60804-7/fulltext (accessed August 24, 2010).

Anglim, P. P., T. A. Alonzo, and I. A. Laird-Offringa. 2008. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Molecular Cancer 7(81).

Ariyanchira, S. 2008. BioMarket trends: orphan drug arena driven by biologics. Genetic Engineering and Biotechnology News 21(1). http://www.genengnews.com/gen-articles/biomarket-trends-orphan-drug-arena-driven-by-biologics/2318/ (accessed August 10, 2010).

Arnon, S. S. 2007. Creation and development of the public service orphan drug human botulism immune globulin. Pediatrics 119(4):785-789. http://www.cdph.ca.gov/programs/ibtpp/Documents/Peds-Creatn-Devlpmt-BIG-IV-2007.pdf (accessed August 10, 2010).

Asamoah, A. K., and J. M. Sharfstein. 2010. Transparency at the Food and Drug Administration. New England Journal of Medicine 362:25. http://www.nejm.org/doi/pdf/10.1056/NEJMp1005202 (accessed August 20, 2010).

Asbury, C. H. 1985. Orphan Drugs, Medical Versus Market Value. Lexington, MA: Lexington Books.

Asbury, C. H. 1991. The Orphan Drug Act: the first 7 years. Journal of the American Medical Association 265(7):893-897.

ASH (American Society of Hematology). 2007. Toward a New Research Paradigm: Building a New Sickle Cell Disease Research Agenda. http://www.hematology.org/Advocacy/Policy-Statements/2680.aspx (accessed August 10, 2010).

Ashlock, M. 2010. Increasing the therapeutic options for individuals with rare diseases. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 23.

ASHP (American Society of Health-System Pharmacists). 2010. Manufacturer PAPs. http://www.ashp.org/Import/PRACTICEANDPOLICY/PracticeResourceCenters/PatientAssistancePrograms/ManufacturerPAPs.aspx (accessed August 10, 2010).

Atkins, D., J. Siegel, and J. Slutsky. 2005. Making policy when the evidence is in dispute. Health Affairs 24(1):102-113.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Austin, C. P. 2010. NIH translational research for rare diseases and orphan products: NCGC and TRND. Presentation to the IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4.

Australia. 1989. Therapeutic Goods Act. http://www.comlaw.gov.au/ComLaw/Legislation/ActCompilation1.nsf/0/840CB0162B421D54CA256FBF00121547/$file/TherapeuticGoods1989_WD02.pdf (accessed August 10, 2010).

Australian Bureau of Statistics. 2008. 3105.0.65.001 Australian Historical Population Statistics. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3105.0.65.0012008?OpenDocument (accessed August 10, 2010).

Aylward, E. H. 2007. Change in MRI striatal volumes as a biomarker in preclinical Hunting-ton’s disease. Brain Research Bulletin 72(2-3):152-158.

Aymé, S. 2009. From ICD10 to ICD11: proposal for a general approach and incorporation of rare diseases. Presentation to the Committee for Orphan Medicinal Products (COMP), European Medicines Agency, London. April 9. http://www.eurordis.org/IMG/pdf/ICD_revision_S_Ayme_EMEA_March_09.pdf (accessed August 10, 2010).

Azuma, H., N. Paulk, A. Ranade, C. Dorrell, M. Al-Dhalimy, E. Ellis, S. Strom, et al. 2007. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nature Biotechnology 25(8):903-910. http://kaylab.stanford.edu/manuscripts/NBT07Azuma.pdf (accessed August 10, 2010).

Baily, M. A., and T. H. Murray. 2008. Ethics, evidence, and cost in newborn screening. Hastings Center Report 38(3):23-31. http://www.thehastingscenter.org/uploadedFiles/Publications/HCR/Articles/2008_May-June/hcr_2008_may_jun_early_release1.pdf (accessed August 10, 2010).

Bainbridge J. W. B., A. J. Smith, S. S. Barker, S. Robbie, R. Henderson, K. Balaggan, A. Viswanathan, et al. 2008. Effect of gene therapy on visual function in Leber’s congenital amaurosis. New England Journal of Medicine 358:2231-2239.

Beitz, J. 2006. Approval letter to Genzyme Corporation for BLA 125141/0 [Alglucosidease alfa/Myozyme]. April 28. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/125141s0_LTR.pdf (accessed August 24, 2010).

Beitz, J. 2010. Approval letter to Orphan Europe for NDA 022562 [Carbaglu]. March 18. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022562s000ltr.pdf (accessed August 19, 2010).

Bellingham, M. C. 2010. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neuroscience & Therapeutics March 10 [e-pub ahead of print].

Benderly, B. L. 2009. The End of Blinding Trachoma Among The World’s Poor Is in Sight. http://www.dcp2.org/features/75 (accessed August 10, 2010).

Benson, D.A., I. Karsch-Mizrachi, D. J. Lipman, J. Ostell, and D. L.Wheeler. 2008. GenBank. Nucleic Acids Research 36 (Database issue):D25-30.

Berger, E. 2009. Medicare’s Inpatient New Technology Add-on: The Trials of InfraReDx, the Triumph of Spiration. http://larchmontstrategic.blogspot.com/2009/08/medicares-inpatient-new-technology-add.html (accessed August 10, 2010).

Bernad, D. M. 2009. Humanitarian use device and humanitarian device exemption regulatory programs: pros and cons. Expert Reviews 6(2):137-145.

Berry, D. A. 2006. A guide to drug discovery: Bayesian clinical trials. Nature Reviews 5:27-36.

Beutler, E., T. Gelbart, P. Lee, R. Trevino, M. A. Fernandez, and V. F. Fairbanks. 2000. Molecular characterization of a case of atransferrinemia. Blood 96(13):4071-4074.

Billiondollarwoman. 2010. Comment on: The World’s Most Expensive Drugs. http://rate.forbes.com/comments/CommentServlet?op=cpage&sourcename=story&StoryURI=2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html (accessed August 10, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Bonabeau, E., N. Bodick, and R. W. Armstrong. 2008. A more rational approach to new product development. Harvard Business Review, March. http://people.icoserver.com/users/eric/hbr_NPD.pdf (accessed August 10, 2010).

Boodman, S. G. 2009. Annoying bug turned out to be much more. Washington Post, November 3. http://www.washingtonpost.com/wp-dyn/content/article/2009/11/02/AR2009110202432.html (accessed August 10, 2010).

Booz Allen Hamilton Inc. 2008. Independent Evaluation of FDA’s First Cycle Review Performance: Final Report. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm127982.pdf (accessed August 10, 2010).

Brancati, F., A. Sarkozy, and B. Dallapiccola. 2006. KBG syndrome.2006. KBG syndrome. OJRD (Orphanet Journal of Rare Diseases). http://www.ojrd.com/content/1/1/50 (accessed August 10, 2010).

Braunschweig, F. 2007. Therapeutic and diagnostic role of electrical devices in acute heart failure. Heart Failure Reviews 12(2):157-166.

Brodsky, R. A. 2009. How I treat paroxysmal nocturnal hemoglobinuria. Blood 113(26): 6522-6527.

Brooks A. D., W. A. Wells, T. D. McLean, R. Khanna, R. Coghlan T. Mertenskoetter, L. A. Privor-Dumm, et al. 2010. Ensuring that developing countries have access to new healthcare products: the role of product development partnerships. Innovation Strategy Today 3:1-5. http://www.ipmglobal.org/pdfs/english/ipm_publications/2010/PDPAccess-InnovationStratToday-Jan2010.pdf (accessed August 23, 2010).

Budd, T. M., and K. A. Liebman. 2009. Annual Review of Medical Device Patent Litigation. http://www.faegre.com/showarticle.aspx?Show=9611 (accessed August 10, 2010).

Butcher, L. 2009. When should insurers cover off-label drug usage? Managed Care, May. http://www.managedcaremag.com/archives/0905/0905.offlabel.html (accessed August 10, 2010).

Campbell, A. 2004. Appendix B: State regulation of medical research with children and adolescents: an overview and analysis. In Ethical Conduct of Clinical Research Involving Children. Washington, DC: The National Academies Press. Pp. 320-383.

Campbell, E. G., B. R. Clarridge, M. Gokhale, L. Birenbaum, S. Hilgartner, N. A. Holtzman, and D. Blumenthal. 2002. Data withholding in academic genetics: evidence from a national survey. Journal of the American Medical Association 287(4):473-480.

Campbell, G. 2008. Statistics in medical devices and diagnostics. Presentation at the AdvaMed-FDA Statistics Workshop, Bethesda, MD. April 16. http://www.amstat.org/sections/sigmedd/Advamed/Advamed08/presentation/GCampbell_Advamed-FDA_Statistics_4-08.pdf (accessed August 10, 2010).

Campbell, G. 2009. Bayesian statistics at the FDA: The trailblazing experience with medical devices. Presentation at Rutgers Biostatistics Day, New Brunswick, NJ. April 9. http://www.stat.rutgers.edu/iob/bioconf09/slides/Campbell.pdf (accessed August 9, 2010).

Campbell, R. M. 2007. Ensuring safe medicines and medical devices for children. Testimony before the Committee on Health, Education, Labor and Pensions, U.S. Senate, Washington, DC, March 27. http://www.aap.org/advocacy/washing/therapeutics/docs/campbell.pdf (accessed August 27, 2010).

Campeau, P. M., C. R. Scriver, and J. J. Mitchell. 2008. A 25-year longitudinal analysis of treatment efficacy in inborn errors of metabolism. Molecular Genetics and Metabolism 95(1-2):11-16.

Cannom, D. S., and E. N. Prystowsky. 2004. The evolution of the implantable cardioverter defibrillator. Pacing and Clinical Electrophysiology 27(3):419-421.

Carmichael, M. 2010. Would regulation kill genetic testing? Newsweek, June 4. http://www.newsweek.com/2010/06/04/would-regulation-kill-genetic-testing.html (accessed September 1, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Cartier N., S. Hacein-Bey-Abina, C. C. Bartholomae, G. Veres, M. Schmidt, I. Kutschera, M.Vidaud, et al. 2009. Lentiviral-mediated gene therapy of hematopoietic stem cells delays disease progression in patients with a fatal brain disorder. Science 326(5954):818-823.

Carver, K. H. C. 2010. Companion diagnostics: evolving FDA regulation and issues for resolution. In In Vitro Diagnostics: The Complete Regulatory Guide, edited by S. D. Danzis and E. J. Flannery. Washington, DC: The Food and Drug Law Institute.

Cassidy, A. 2009. Coverage and Payment for Prescription Drugs Under Medicare Part B: A Complex Patchwork. National Health Policy Forum Background Paper. http://www.nhpf.org/library/details.cfm/2755 (accessed August 9, 2010).

Cassidy, S. B., and D. J. Driscoll. 2009. Prader-Willi syndrome. European Journal of Human Genetics 17:3-13.

Caves, R. E., M. D. Whinston, and M. A. Hurwitz. 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity. Microeconomics 1991:1-48.

CBTRUS (Central Brain Tumor Registry of the United States). 2010. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. http://www.cbtrus.org/2007-2008/2007-20081.html (accessed August 9, 2010).

CDC (Centers for Disease Control and Prevention). 2005. Marine Toxins. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/marinetoxins_g.htm (accessed August 9, 2010).

CDC. 2007a. Hemochromatosis for Health Care Professionals: Epidemiology: Prevalence. http://www.cdc.gov/ncbddd/hemochromatosis/training/epidemiology/prevalence.htm (accessed August 9, 2010).

CDC. 2007b. Malaria surveillance—United States, 2005. Morbidity and Mortality Weekly Reports 56(SS06):23-38. http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5606a2.htm (accessed December 1, 2010).

CDC. 2008a. Leishmania Infection. http://www.cdc.gov/ncidod/dpd/parasites/leishmania/factsht_leishmania.htm#get_us (accessed August 9, 2010).

CDC. 2008b. Nocardiosis. http://www.cdc.gov/nczved/divisions/dfbmd/diseases/nocardiosis/technical.html (accessed August 9, 2010).

CDC. 2008c. Schistosomiasis. http://www.cdc.gov/ncidod/dpd/parasites/schistosomiasis/factsht_schistosomiasis.htm (accessed August 9, 2010).

CDC. 2009a. Dengue Epidemiology. http://www.cdc.gov/dengue/epidemiology/index.html (accessed August 9, 2010).

CDC. 2009b. Fiscal Year 2009: Justification of Estimates for Appropriation Committees. http://www.cdc.gov/fmo/PDFs/FY09_CDC_CJ_Final.pdf (accessed August 9, 2010).

CDC. 2009c. HIV/AIDS Surveillance Report: Cases of HIV Infection and AIDS in the United States and Dependent Areas, 2007. http://www.cdc.gov/hiv/topics/surveillance/basic.htm#hivest (accessed August 9, 2010).

CDC. 2009d. Newborn Screening Translation Research Initiative. http://www.cdcfoundation.org/programs/lifestyles/index.aspx#newborn (accessed August 9, 2010).

CDER (Center for Drug Evaluation and Research, Food and Drug Administration). 1998. The CDER Handbook. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM198415.pdf (accessed August 9, 2010).

CDER. 2002. Guidance for Industry: Carcinogenicity Study Protocol Submissions. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078924.pdf (accessed August 9, 2010).

CDER. 2003. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf (accessed August 24, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

CDER. 2006. Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf (accessed August 9, 2010).

CDER. 2007. Guidance for Industry: Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071575.pdf (accessed August 9, 2010).

CDER. 2009. CDER Medical Policy Coordinating Committee. Manual of Policies and Procedures November 2. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/UCM188694.pdf (accessed August 20, 2010).

CDER-CBER (Center for Biologics Evaluation and Research). 1996. Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf (accessed August 24, 2010).

CDER-CBER. 1997. Guidance for Industry: S6 Preclinical Evaluation of Biotechnology-Derived Pharmaceuticals. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074957.pdf (accessed August 24, 2010).

CDER-CBER. 1998. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf (accessed August 24, 2010).

CDER-CBER. 2002a. Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126838.pdf (accessed August 24, 2010).

CDER-CBER. 2002b. Guidance for Industry: Special Protocol Assistance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf (accessed August 24, 2010).

CDER-CBER. 2009. Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf (accessed August 24, 2010).

CDER-CBER. 2010a. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (Draft). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf (accessed August 24, 2010).

CDER-CBER. 2010b. Guidance for Industry: Non-Inferiority Clinical Trials. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf (accessed August 24, 2010).

CDMRP (Congressionally Directed Medical Research Programs, Department of Defense). 2008. FY 2008 Annual Report: Contents. http://cdmrp.army.mil/pubs/annreports/2008annrep/default.shtml (accessed August 24, 2010).

CDRH (Center for Devices and Radiological Health, Food and Drug Administration). 2009. Humanitarian Use Device: Overview. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/HumanitarianDeviceExemption/default.htm (accessed August 9, 2010).

CDRH. 2010a. CDRH Preliminary Internal Evaluations—Volume 1. August. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220784.pdf (accessed September 3, 2010).

CDRH. 2010b. Office of Device Evaluation. http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115879.htm#3 (accessed August 9, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

CDRH-CBER. 2007. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff: In Vitro Diagnostic Multivariate Index Assays. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071455.pdf (accessed August 24, 2010).

CDRH-CBER. 2010. Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and FDA Staff—Humanitarian Device Exemption (HDE) Regulation: Questions and Answers. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm110194.htm (accessed August 24, 2010).

CDRH-OSB (Office of Surveillance and Biometrics). 2010. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071121.pdf (accessed August 24, 2010).

Celgene. 2010. Thalomid®: System for Thalomide Education and Prescribing Safety. http://www.thalomid.com/steps_program.aspx (accessed August 9, 2010).

CFF (Cystic Fibrosis Foundation). 2008. Research Milestones. http://www.cff.org/research/ResearchMilestones/ (accessed August 9, 2010).

CFF. 2009. Cystic Fibrosis Foundation Patient Registry 2008 Annual Data Report. http://www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf (accessed August 9, 2010).

CFF. Undated a. CF Basic Research Centers. http://www.cff.org/aboutCFFoundation/Locations/ResearchCenters/ (accessed August 9, 2010).

CFF. Undated b. CF Foundation-Accredited Care Centers. http://www.cff.org/treatments/CareCenterNetwork/CFFoundation-accreditedCareCenters/ (accessed August 9, 2010).

CFSAN (Center for Food Safety and Nutrition), Food and Drug Administration. 2007. Guidance for Industry: Frequently Asked Questions About Medical Foods. College Park, MD: FDA. http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/MedicalFoods/UCM054048#q1 (accessed August 9, 2010).

Chamberlain, J. R., U. Schwarze, P. Wang, R. K. Hirata, K. D. Hankenson, J. M. Pace, R. A. Underwood, et al. 2004. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 303:1198. http://www.sciencemag.org/cgi/reprint/303/5661/1198.pdf (accessed August 23, 2010).

Chan, K., and J. M. Puck. 2005. Development of population-based newborn screening for severe combined immunodeficiency. Journal of Allergy and Clinical Immunology 115:391-398.

Chong, C. R., and D. J. Sullivan, Jr. 2007. New uses for old drugs. Nature 448:645-646. August 8.

Choudhry, N. K., J. L. Lee, J. Agnew-Blais, C. Corcoran, and W. H. Shrank. 2009. Drug company-sponsored patient assistance programs: A Viable Safety Net? Health Affairs 28(3):827-834.

Citron, P. 2008. Medical device considerations. Presentation to IOM Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC. January 21.

Clinton, C., and H. T. Gazda. 2009. Diamond-Blackfan Anemia. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=diamond-b (accessed August 9, 2010).

Clyde, A. T., L. Bockstedt, J. A. Farkas, and C. Jackson. 2008. Experience with Medicare’s new technology add-on payment program. Health Affairs 27(6):1632-1641.

CMS (Centers for Medicare and Medicaid Services). 2000. Clinical Trials. http://www.cms.gov/manuals/downloads/Pub06_PART_35.pdf (accessed August 9, 2010).

CMS. 2006. Guidance for the Public, Industry, and CMS Staff—National Coverage Determinations with Data Collection as a Condition of Coverage: Coverage with Evidence Development. July. https://www.cms.gov/mcd/ncpc_view_document.asp?id=8 (accessed August 9, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

CMS. 2007. CMS Manual System. http://www.cms.gov/Transmittals/Downloads/R74NCD.pdf (accessed August 9, 2010).

CMS. 2009a. 2010 Combined Call Letter. Prescription Drug Coverage Contracting. March 30. http://www.cms.gov/PrescriptionDrugCovContra/Downloads/2010CallLetter.pdf (accessed August 19, 2010).

CMS. 2009b. Medicaid Drug Rebate Program: Overview. http://www.cms.gov/MedicaidDrugRebateProgram/ (accessed August 9, 2010).

CMS. 2009c. Medicare program; proposed changes to the hospital inpatient prospective payment systems for acute care hospitals and fiscal year 2010 rates and to the long-term care hospital prospective payment system and rate year 2010 Rates; proposed rule. Federal Register 74(98):24080-24686. http://edocket.access.gpo.gov/2009/pdf/E9-10458.pdf (accessed August 9, 2010).

CMS. 2009d. Medicare Enrollment: National Trends 1966-2008. http://www.cms.gov/MedicareEnRpts/Downloads/HISMI08.pdf (accessed August 9, 2010).

CMS. 2010. Medicare & You 2010. http://www.medicare.gov/publications/pubs/pdf/10050.pdf (accessed August 9, 2010).

Cohen, W. M., and J. P. Walsh. 2008. Real impediments to biomedical research. In Innovation Policy and the Economy, edited by A. B. Jaffe, J. Lerner, and S. Stern. Chicago, IL: University of Chicago Press. Pp. 1-30.

Cohn, R. D., C. van Erp, J. P. Habasi, A. A. Soleimani, E. C. Klein, M. T. Lisi, M. Gamradt, et al. 2007. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nature Medicine 13:204-210. E-pub January 21.

Collins, F. S. 2009. Implementing personalized medicine: scientific and translational challenges. Presentation to AAAS Personalized Medicine: Planning for the Future Colloquium, Washington, DC. October 26. http://www.aaas.org/spp/PM/ppts/Collins.pdf (accessed August 9, 2010).

Collins, K. L. 2004. Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health. Perspectives in Biology and Medicine. 47(1):100-109.

Cook-Deegan, R. 2008. Gene patents. In From Birth to Death and Bench to Clinic: The Hastings Center Bioethics Briefing Book for Journalists, Policymakers, and Campaigns, edited by Mary Crowley. Garrison, NY: The Hastings Center. Pp. 69-72. http://www.thehastingscenter.org/uploadedFiles/Publications/Briefing_Book/gene%20patents%20chapter.pdf (accessed August 9, 2010).

Coombs, A. 2009. Rare nature of mushroom poisoning means drug trials rarer still. Nature Medicine 15(3).

Cornetta, K., and B. Carter. 2010. Letter on Behalf of the American Society of Gene & Cell Therapy to Francis Collins, Director, NIH. March 10. http://www.asgct.org/UserFiles/file/Francis%20Collins%20Letter.pdf (accessed September 24, 2010).

Corr, P. 2008. New business models addressing global health: a framework for private equity. Presentation at IOM Forum on Drug Discovery, Development, and Translation Workshop on Breakthrough Business Models, Washington, DC. June 23.

Cortazar, P. 2007. Clinical review for NDA 22042 [Evista / Raloxifene Hydrochloride]. CDER Medical Review Part 1 Application Number: 22042. September 6. p. 16. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022042s000_MedR_P1.pdf (accessed August 19, 2010).

Coté, T. 2009. The state of the Orphan Drug Act. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. August 12.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Coté, T. 2010. Orphans at FDA: the fundamentals. Presentation at the American Course on Drug Development and Regulatory Sciences, San Francisco, CA. February 23.

C-Path (Critical Path Institute). 2008. FDA and EMEA Conclude That New Renal Safety Biomarkers Are Qualified for Specific Regulatory Purposes. http://www.c-path.org/pdf/PSTC_nephro_VXDS_summary_final.pdf (accessed August 9, 2010).

C-Path. 2009a. Coalition Against Major Disease: Workscope 1.1. http://www.c-path.org/pdf/CAMDWorkScope.pdf (accessed August 9, 2010).

C-Path. 2009b. The Predictive Safety Testing Consortium. http://www.c-path.org/pdf/PSTC_GeneralInfo_08-28-09.pdf (accessed August 9, 2010).

CPI (Critical Path Initiative). 2010. The Critical Path Initiative: Report on Key Achievements in 2009. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/UCM221651.pdf (accessed September 24, 2010).

CTF (Children’s Tumor Foundation). 2009. 2008 Annual Report. http://www.ctf.org/images/stories/2008_annual_report_final.pdf (accessed August 9, 2010).

CTSA (Clinical and Translational Science Awards, NIH). 2010. Evaluation—IRB Issues in Evaluation. http://www.ctsaweb.org/index.cfm?fuseaction=committee.viewCommittee&com_ID=461&abbr= (accessed August 10, 2010).

CTXinfo.org (Cerebrotendinous xanthomatosis). 2010. Latest News: February 28. http://www.ctxinfo.org/index.html (accessed August 9, 2010).

Dale, D. C., and D. C. Link. 2009. The many causes of severe congenital neutropenia. New England Journal of Medicine 360(1):3-5.

D’Andrea, A. D. 2010. Susceptibility pathways in Fanconi’s anemia and breast cancer. New England Journal of Medicine 362:1909-1919.

Defazio, G., G. Abbruzzese, P. Livrea, and A. Berardelli. 2004. Epidemiology of primary dystonia. Lancet Neurology 3(11):673-678.

Delude, C. 2009. Tangier disease: one island’s treasure. Proto Magazine Fall:16-21. http://protomag.com/statics/tangiers.pdf (accessed August 9, 2010).

Derbis, J., B. Evelyn, and J. McMeekin. 2008. FDA initiative aims to remove unapproved drugs from market. Pharmacy Today August:21-22.

de Siqueira, I. C., J. Dias, H. Ruf, E. A. G. Ramos, E. A. Pires Maciel, A. Rolim, L. Jabur, et al. 2005. Chromobacterium violaceum in siblings, Brazil. Emerging Infectious Diseases (11)9. http://www.cdc.gov/ncidod/EId/vol11no09/pdfs/05-0278.pdf (accessed August 9, 2010).

Dhruva, S. S., L. A. Bero, and R. F. Redberg. 2009. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. Journal of the American Medical Association 302(24):2679-2685.

Dietz, H. C. 2009. Marfan Syndrome. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=marfan (accessed August 9, 2010).

Dietz, H. C. 2010. New therapeutic approaches for Mendelian disorders. New England Journal of Medicine 363:852-863. http://www.nejm.org/doi/full/10.1056/NEJMra0907180?query=TOC (accessed September 1, 2010).

DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22(2003):151-185.

DiMasi, J. A., L. Feldman, A. Seckler, and A.Wilson. 2010. Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics 87:272-277.

Dimond, P. F. 2009. Big PhRMA adopting orphan drug strategy. Genetic Engineering & Biotechnology News. http://www.genengnews.com/analysis-and-insight/big-pharma-adopting-orphan-drug-strategy/71053206/ (accessed August 9, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

DNDi (Drugs for Neglected Diseases Initiative). 2009. Pfizer and DNDi Advancing International Research Efforts in the Fight Against Neglected Tropical Diseases (press release). http://www.dndi.org/press-releases/2009/565-pfizer-and-dndi-advancing-international-research-efforts-in-the-fight-against-neglected-tropical-diseases.html (accessed August 9, 2010).

DOJ (Department of Justice). 2009. Stryker Biotech and Its Top Management Indicted for Illegal Promotion of Medical Devices Used in Invasive Surgeries (press release), October 28. http://www.fda.gov/downloads/NewsEvents/Newsroom/PressAnnouncements/UCM188306.pdf (accessed August 24, 2010).

Dorman, D. 2007. Testimony submitted by the National Organization for Rare Disorders before the Social Security Administration Public Hearing on Compassionate Allowances, Washington, DC. December 4.

Dorman, D. 2008. Statement of Diane Dorman, Vice President for Public Policy National Organization for Rare Disorders (NORD), to FDA Infectious Diseases Planning Committee, Washington, DC. April 28. http://www.rarediseases.org/pdf/FDA_Infectious_Diseases_Planning_Com_4-22-08.pdf (accessed August 9, 2010).

Dorsey, E. R., J. de Roulet, J. P. Thompson, J. I. Reminick, A. Thai, Z. White-Stellato, C. A. Beck, et al. 2010. Funding of US biomedical research, 2003-2008. Journal of the American Medical Association 303(2):137-143.

Douglas, J. 2010. Update: Shire plans to undercut Cerezyme as profit rises. Dow Jones Newswires, February 19. http://www.nasdaq.com/aspx/companynewsStoryPrint.aspx?storyid=201002190850dowjonesdjonline000444 (accessed August 9, 2010).

Doulton, D. M. 2010. From cradle to commencement: transitioning pediatric sickle cell disease patients to adult providers. Journal of Pediatric Oncology Nursing 27(2):119-123.

Dreifus, C. 2009. Researcher behind the drug Gleevec: a conversation with Brian Druker. New York Times, November 2. http://www.nytimes.com/2009/11/03/science/03conv.html (accessed August 9, 2010).

Dudley J. T., R. Tibshirani, T. Deshpande, and A. J. Butte. 2009. Disease signatures are robust across tissues and experiments. Molecular Systems Biology 5:307. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758720/pdf/msb200966.pdf (accessed August 9, 2010).

Duffner, P. K., V. S. Caviness, R. W. Erbe, M. C. Patterson, K. R. Schultz, D. A. Wenger, and C. Whitley. 2009. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genetics in Medicine 11(6):450-454.

Duggan, M. 2010. The effect of Medicare Part D on pharmaceutical prices and utilization. American Economic Review 100(1):590-600.

Duggan, M., and F. M. S. Morton. 2006. The distortionary effects of government procurement: evidence from Medicaid prescription drug purchasing. Quarterly Journal of Economics 121(1):1-30.

Duncan, D. E. 2009. Enlisting computers to unravel the true complexity of disease. New York Times, August 24. http://www.nytimes.com/2009/08/25/science/25prof.html (accessed August 9, 2010).

Duncan, M. W., and S. W. Hunsucker. 2005. Proteomics as a tool for clinically relevant biomarker discovery and validation. Experimental Biology and Medicine 230(11):808-817.

Dykxhoorn, D. M., and J. Lieberman. 2006. Knocking down disease with siRNAs. Cell 126(2):231-235.

Eastman, P. 2005. Reimbursement policies discourage off-label drug use. Oncology Times 27(20):8, 10.

El-Khatib, F. H., S. J. Russell, D. M. Nathan, R. G. Sutherlin, and E. R. Damiano. 2010. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Science Translational Medicine 2(27):27ra27.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Elsas, L. J. 2007. Galactosemia. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=galactosemia (accessed August 9, 2010).

EMEA (European Medicines Agency). 2008. Annual Report, 2007. London. http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2009/12/WC500016591.pdf (accessed December 1, 2010).

Entrepreneur Newsletter. 2006. NMT medical voluntarily withdraws Cardioseal PFO HDE(Biotech Equipment Update, October 1). http://www.entrepreneur.com/tradejournals/article/151492685.html (accessed August 9, 2010).

EPI (Economic Policy Institute). 2009. Employer-Sponsored Health Insurance Erosion Continues: Unabated Declines in Coverage Since 2000 Are Expected to Worsen Through 2009. http://epi.3cdn.net/6356d48ae59f625af6_xxm6bnyn2.pdf (accessed August 9, 2010).

Escolar, M. L., M. D. Poe, H. R. Martin, and J. Kurtzberg. 2006. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics 118(3):e879-e889.

Eurodis. 2005. Rare diseases in numbers. European Conference on Rare Diseases, Luxembourg, June 21-22. http://ec.europa.eu/health/ph_threats/non_com/ev_20050622_co01_en.pdf (accessed August 6, 2010).

European Commission, Health & Consumer Protection Directorate-General. 2007. Public Consultation, Rare Diseases: Europe’s Challenges. http://ec.europa.eu/health/ph_threats/non_com/docs/raredis_comm_draft.pdf (accessed August 6, 2010).

European Union. 1999. Regulation (EC) No. 141/2000. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:EN:PDF (accessed August 6, 2010).

Eurostat. 2010. Total Population. http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&language=en&pcode=tps00001&tableSelection=1&footnotes=yes&labeling=labels&plugin=1 (accessed August 6, 2010).

Faik, I., E. de Carvalho, and J. Kun. 2009. Parasite-host interaction in malaria: genetic clues and copy number variation. Genome Medicine 1(9):82.

Fanelli, D. 2010. Do pressures to publish increase scientists’ bias? An empirical support from US states data. PLoS ONE 5(4): e10271. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0010271;jsessionid=EB8BEAAC2BD41631E15776993436B1B4.ambra01 (accessed August 3, 2010).

Farag-El-Massah, S., M. M. Braun, J. Cloyd, S. Schondelmeyer, K. Xu, M. Thomas, D. Lewis, and T. R. Coté. 2009. Quantitative description of FDA designated and approved orphan drugs and biologics. Poster presentation at annual meeting of the Drug Information Association, San Diego, CA. June 22.

Farmer, J. 2009. Accelerating rare diseases research and orphan product development: a FARA [Friedreich’s Ataxia Research Alliance] perspective. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. November 23.

Farrell, E., and J. Usuka. 2008. Pharmacogenomics and drug development: the impact of U.S. FDA postapproval tracking on clinical pharmacology. Personalized Medicine 5(2):133-139.

Faurisson, F. 2004. EurordisCare2: Survey of Diagnostic Delays, 8 Diseases, Europe. http://archive.eurordis.org/imprimer.php3?id_article=454 (accessed August 6 2010).

FDA (Food and Drug Administration). 1996. Guideline for Industry: The Need for Long-Term Rodent Carcinogenicity Studies of Pharmaceuticals. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074911.pdf (accessed August 6, 2010).

FDA. 2004. Challenge and Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf (accessed September 24, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

FDA. 2009a. Fast Track, Accelerated Approval and Priority Review. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccesstoImportantNewTherapies/ucm128291.htm#priorityreview (accessed August 6, 2010).

FDA. 2009b. Frequently Asked Questions About Therapeutic Biological Products. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm (accessed August 6, 2010).

FDA. 2009c. Orphan Products: Hope for People with Rare Diseases. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143563.htm (accessed August 6, 2010).

FDA. 2009d. The Critical Path Initiative: Report on Key Achievements in 2009. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM219432.pdf (accessed August 9, 2010).

FDA. 2010a. FDA Drug Safety Communication: Risk of Progressive Multifocal Leukoencephalopathy (PML) with the Use of Tysabri (Natalizumab). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm (accessed August 6, 2010).

FDA. 2010b. FDA Transparency Initiative: Draft Proposals for Public Comment Regarding Disclosure Policies of the U.S. Food And Drug Administration. http://www.fda.gov/downloads/AboutFDA/WhatWeDo/FDATransparencyTaskForce/TransparencyReport/GlossaryofAcronymsandAbbreviations/UCM212110.pdf (accessed August 6, 2010).

FDA. 2010c. FY 2011 Food and Drug Administration Congressional Justification. http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/BudgetReports/ucm202301.htm (accessed August 6, 2010).

FDA. Undated. FY 2008 Performance Report to the President and the Congress for the Prescription Drug User Fee Act. http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/ucm209305.htm (accessed August 6, 2010).

FDA Science Board. 2007. FDA Science and Mission at Risk: Report of the Subcommittee on Science and Technology. http://www.fda.gov/ohrms/DOCKETS/ac/07/briefing/2007-4329b_02_01_FDA%20Report%20on%20Science%20and%20Technology.pdf (accessed August 6, 2010).

Feigal, D. 2002. CDRH vision—total product lifecycle (slide). http://www.fda.gov/ohrms/dockets/ac/01/slides/3799s1_11_Feigal/sld002.htm (accessed August 6, 2010).

Feigal, D. W., S. N. Gardner, and M. McClellan. 2003. Ensuring safe and effective medical devices. New England Journal of Medicine 348(3):191-192.

Feinberg, A. P., and B. R. Williams. 2003. Wilms’ tumor as a model for cancer biology. Methods in Molecular Biology 222:239-248.

Filipovich, A. H., J. Johnson, and K. Zhang. 2007. WAS-Related Disorders. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=was (accessed September 7, 2010).

Fischer A., P. Borensztein, and C. Roussel. 2005. The European Rare Diseases Therapeutic Initiative. PLoS Medicine 2(9):e243. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0020243 (accessed August 6, 2010).

Fisher, W. O. 2002. Key disclosure issues for life sciences companies: FDA product approval, clinical test results, and government inspections. Michigan Telecommunications and Technology Law Review 8(115):115-193.

Flannery, E. J., and P. B. Hutt. 1985. Balancing competition and patent protection in the drug industry: The Drug Price Competition and Patent Term Restoration Act of 1984. Food Drug Cosmetic Law Journal 40:269-309.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Fleming, T. R. 2005. Surrogate endpoints and FDA’s accelerated approval process. Health Affairs 24(1):67-78. http://content.healthaffairs.org/cgi/content/full/24/1/hits=10&FIRSTINDEX=0&ck=nck&FULLTEXT=surrogate+endpoints+and+FDA%27s+accelerated+approval+process&SEARCHID=1&gca=healthaff%3B24%2F1%2F67&&eaf (accessed August 6, 2010).

FNIH (Foundation for the National Institutes of Health). 2010. How We Work. http://www.fnih.org/about/how-we-work (accessed August 20, 2010).

Forrest, C. B., S. C. Groft, R. J. Bartek, and Y. Rubinstein. 2010. The case for a global rare diseases registry. Lancet, published online August 2.

Fox, M. 2010. New collaboration aims to speed TB drugs to market. Reuters. March 18.

Frakt, A. B., and S. D. Pizer. 2009. Beneficiary price sensitivity in the Medicare prescription drug plan market. Health Economics 19(1):88-100.

Frank, R. G. 2007. The ongoing regulation of generic drugs. New England Journal of Medicine 357(20):1993-1996.

Frank, R. G., and J. P. Newhouse. 2008. Should drug prices be negotiated under part D of Medicare? and if so, how? Health Affairs 27(1):33-43.

Frank, R. G., and D. S. Salkever. 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6(1):75-90.

Frohnmayer, D., and L. Frohnmayer. 2009. Fanconi Anemia Research Fund. Presentation (by phone) to the IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. November 23.

Fugh-Berman, A., and D. Melnick. 2008 Off-label promotion, on-target sales. Public Library of Science Medicine 5(10):e210. http://www.plosmedicine.org/article/info:doi%2F10.1371%2Fjournal.pmed.0050210 (accessed August 6, 2010).

GAO (Government Accountability Office). 2009a. New Drug Approval: FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints. GAO-09-866. http://www.gao.gov/new.items/d09866.pdf (accessed August 6, 2010).

GAO. 2009b. Protecting public health through enhanced oversight of medical products. In High Risk Series: An Update. Report No. GAO 09-271. Washington, DC. Pp. 15-21.

GAO. 2010a. Direct-to-Consumer Genetic Tests; Misleading Test Results Are Further Complicated by Deceptive Marketing and Other Questionable Practices: Testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives, July 22. http://www.gao.gov/new.items/d10847t.pdf (accessed September 1, 2010).

GAO. 2010b. Medicare Part D: Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier. http://www.gao.gov/new.items/d10242.pdf (accessed August 6, 2010).

Garnett, C. 2010. New undiagnosed diseases program awash in potential patients. NIH Record LXII(1). http://nihrecord.od.nih.gov/newsletters/2010/01_08_2010/story2.htm (accessed August 28, 2010).

Gartner, L. M., and F. R. Greer. 2003. Prevention of rickets and vitamin D deficiency: new guidelines for vitamin D intake. Pediatrics 111(4):908-910.

Gassman, O., G. Reepmeyer, and M. v. Zedtwitz. 2008. Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry, 2nd ed. New York: Springer.

Gelijns, A. C., B. Killelea, M. Vitale, V. Mankad, and A. Moskowitz. 2006. Appendix C: The dynamics of pediatric device innovation: putting evidence in context. In Safe Medical Devices for Children. Washington, DC: The National Academies Press. Pp. 302-326.

Genentech. 2010. Herceptin Development Timeline. http://www.gene.com/gene/products/information/oncology/herceptin/timeline.html (accessed August 5, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Genetic Alliance. 2010. Genetic Alliance Biobank Executive Summary. http://www.biobank.org/english/view.asp?x=1364&id=76 (accessed August 5, 2010).

Genomeweb.com. 2010. CMS approves Iverson clinical study of genetic testing for Warfarin. Genomeweb Daily News. July 26.

Gessen, M. 2008. Blood Matters: From Inherited Illness to Designer Babies, How the World and I Found Ourselves in the Future of the Gene. Orlando, FL: Harcourt.

GHR (Genetics Home Reference). 2007. Pulmonary Arterial Hypertension. http://ghr.nlm.nih.gov/condition=pulmonaryarterialhypertension (accessed August 27, 2010).

Gibbs, J. N. 2010. Oversight of research use only products. Genetic Engineering & Biotechnology News 30(5).

Gillick, M. R. 2009. Controlling off-label medication use. Annals of Internal Medicine 150(5):344-347.

Glaser, C., F. Schuste, S.Yagi, S. Gavali, A. Bollen, C. Glastonbury, R. Raghavan, et al. 2008. Balamuthia amebic encephalitis—California, 1999-2007. Morbidity and Mortality Weekly Report 57(28):768-771. http://www.cdc.gov/mmwr/PDF/wk/mm5728.pdf (accessed August 5, 2010).

Gliklich, R. E., and N. A. Dreyer. 2007. Registries for Evaluating Patient Outcomes: A User’s Guide. Outcome DEcIDE Center, AHRQ Publication Number 07-EHC001-1. http://www.effectivehealthcare.ahrq.gov/repFiles/PatOutcomes.pdf (accessed August 5, 2010).

Glover, G. J. 2007. The influence of market exclusivity on drug availability and medical innovations. AAPS Journal 9(3):34. http://www.aapsj.org/articles/aapsj0903/aapsj0903034/aapsj0903034.pdf (accessed August 20, 2010).

Goodman, J. L. 2010. FDA’s Efforts on Rare and Neglected Diseases: Statement to the Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies. Washington, DC. June 23. http://www.fda.gov/NewsEvents/Testimony/ucm216991.htm (accessed August 5, 2010).

Gordon, E. J., and S. Philpott. 2008. The convergence of research and clinical practice: institutional review board review of humanitarian use device applications. Journal of Empirical Research on Human Research Ethics 3(4):81-89.

Grabowski, G. A., and R. J. Hopkin. 2003. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annual Review of Genomics and Human Genetics 4:403-436. http://arjournals.annualreviews.org/doi/abs/10.1146/annurev.genom.4.070802.110415 (accessed September 7, 2010).

Grabowski, H. 2005. Encouraging the development of new vaccines. Health Affairs 24(3): 697-700.

Grabowski, H. G., and J. M. Vernon. 1992. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 35(2):331.

Grant, B. 2008. The Orphan Drug Act turns 25. The Scientist.com 22(10):67.

Greenberg, B. D., D. A. Malone, G. M. Friehs, A. R. Rezai, C. S. Kubu, P. F. Malloy, S. P. Salloway, et al. 2006. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 31(11):2384-2393. http://www.nature.com/npp/journal/v31/n11/full/1301165a.html (accessed August 5, 2010).

Greibel, D. 2010. Memorandum to Julie Beitz, Director, Office of Drug Evaluation III, Center for Drug Evaluation and Research, FDA RE: Approval Action—NDA 022562. Summary Review, NDA 022562 [Carbaglu/carglumic acid]. March 16. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022562s000sumr.pdf (accessed August 19, 2010).

Grenier, D., E. J. Elliott, Y. Zurynski, R. Rodrigues Pereira, M. Preece, R. Lynn, R. von Kries, et al. 2007. Beyond counting cases: public health impacts of national paediatric surveil-2007. Beyond counting cases: public health impacts of national paediatric surveil-Beyond counting cases: public health impacts of national paediatric surveillance units. Archives of Disease in Childhood 92(6):527-533.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Guth, R. A. 2010. Glaxo tries a Linux approach: drug maker shares its research data online in test of open-source principles. Wall Street Journal, May 26. http://online.wsj.com/article/SB10001424052748703341904575266583403844888.html?mod=WSJ_hps_MIDDLEFifthNews (accessed August 5, 2010).

Habashi J. P., D. P. Judge, T. M. Holm, R. D. Cohn, B. L. Loeys, T. K. Cooper, L. Myers, et al. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312(5770):117-121.

Hacein-Bey-Abina, S., J. Hauer, A. Lim, C. Picard, G. P. Wang, C. C. Berry, C. Martinache, et al. 2010. Efficacy of gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine 363(4):355-364.

Haffner, M. E. 1991. Orphan products: origins, progress, and prospects. Annual Review of Pharmacology and Toxicology 31:603-620.

Haffner, M. E. 2006. Adopting orphan drugs—two dozen years of treating rare diseases. New England Journal of Medicine 354(5):445-447.

Haffner, M. E., and P. D. Maher. 2006. The impact of the Orphan Drug Act on drug discovery. Expert Opinion on Drug Discovery 1(6):521-524.

Haffner, M. E., J. Torrent-Farnell, and P. D. Maher. 2008. Does orphan drug legislation really answer the needs of patients? Lancet 371:2041-2044.

Haigh, C. 2008. Gut-derived serotonin regulated bone formation. Endocrine Today, December 25. http://www.endocrinetoday.com/view.aspx?rid=33535 (accessed August 11, 2010).

Hamburg, M. A. 2009. Remarks of Margaret A. Hamburg, M.D., Commissioner of Food and Drugs at AAAS—The Future of Personalized Medicine. http://www.fda.gov/NewsEvents/Speeches/ucm191356.htm (accessed August 5, 2010).

Hamburg, M. A. 2010a. Remarks of Margaret A. Hamburg, M.D., Commissioner of Food and Drugs at the Announcement of FDA/NIH Collaboration. http://www.fda.gov/NewsEvents/Speeches/ucm201687.htm (accessed August 5, 2010).

Hamburg, M. A. 2010b. Statement before the Subcommittee on Agriculture, Rural Redevelopment, Food and Drug Administration, and Related Agencies, U.S. Senate. March 9. http://www.fda.gov/NewsEvents/Testimony/ucm204379.htm (accessed August 5, 2010).

Han, J. 2007. The optimal scope of FDA regulation of genetic tests: meeting challenges and keeping promises. Harvard Journal of Law & Technology 20(2):423-441.

Harris, G. 2010. FDA backtracks and returns drug to market. New York Times, September 3. http://www.nytimes.com/2010/09/04/health/policy/04fda.html (accessed September 9, 2010).

Harvey, W. 2006. Letter IX, to John Vlackveld (24 April 1657). In The Circulation of the Blood. New York: Cosimo. Pp. 200-201.

Heemstra, H. E., S. van Weely, H. A. Büller, H. G. M. Leufkens, and R. L. A. de Vrueh. 2009.2009. Translation of rare disease research into orphan drug development: disease matters. Drug Discovery Today 14(23-24):1166-1173.

Hemsley, K. M., and J. J. Hopwood. 2009. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. International Journal of Clinical Pharmacology and Therapeutics 47(Suppl 1):S118-123.

Hendee, W. R., S. Chien, C. D. Maynard, and D. J. Dean. 2002. The National Institute of Biomedical Imaging and Bioengineering: history, status, and potential impact. Annals of Biomedical Engineering 30:2-10.

Henig, R. M. 2009. What’s wrong with Summer Stiers? New York Times, February 18. http://www.nytimes.com/2009/02/22/magazine/22Diseases-t.html (accessed August 5, 2010).

Henkel, J. 1999. Orphan Drug Law matures into medical mainstay. FDA Consumer Magazine.

Henney, J. 2000. Presentation to Mid-America Coalition on Health Care meeting on managing medical risk, Kansas City, MO. March 27. http://www.fda.gov/NewsEvents/Speeches/ucm054279.htm (accessed August 23, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Heresi, G. A., and R. A. Dweik. 2010. Biomarkers in pulmonary hypertension. Pulmonary Vascular Research Institute Review 2(1):12-16. http://www.pvrireview.org/article.asp?issn=0974-6013;year=2010;volume=2;issue=1;spage=12;epage=16;aulast=Heresi (accessed August 27, 2010).

Herper, M. 2010. The world’s most expensive drugs. Forbes.com. http://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html (accessed August 5, 2010).

Heubi, J. E., K. D. Setchell, and K. E. Bove. 2007. Inborn errors of bile acid metabolism. Seminars in Liver Disease 27(3):282-294.

High, K. A. 2009. The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber’s amaurosis. Transactions of the American Clinical and Climatological Association 120:331-359.

Hildebrandt, F., and W. Zhou. 2007. Nephronophthisis-associated ciliopathies. Journal of the American Society of Nephrology 18(6):1855-1871.

Hill, N. 2010. Spiration® experience with the humanitarian device exemption (HDE) process. Presentation to the IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4.

Hirschhorn, J. N. 2009. Genomewide association studies—illuminating biologic pathways. New England Journal of Medicine 360(17):1699-1701.

Hoffman, G. S. 2006. WG or VF: What’s in a Name? http://www.vasculitisfoundation.org/node/1708.

Holahan, J., and I. Headen. 2010. Medicaid Coverage and Spending in Health Reform: National and State by State Results for Adults At or Below 133% FPL. http://www.kff.org/healthreform/upload/Medicaid-Coverage-and-Spending-in-Health-Reform-National-and-State-By-State-Results-for-Adults-at-or-Below-133-FPL.pdf (accessed August 5, 2010).

Hollaway, R. 2007. Joe Is Not My Son. Alphas, Friends & Family. http://www.alpha-1foundation.org/alphas/joe-is-not-my-son (accessed August 27, 2010).

Horner, M. D., and L. A. G. Ries. 2007. Leukemia (Chapter 29). In SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics, edited by L. A. Ries, J. L. Young, G. E. Keel, M. P. Eisner, Y. D. Lin, and M. D. Horner. NIH Pub. No. 07-6215. National Cancer Institute: Bethesda, MD. http://seer.cancer.gov/publications/survival/surv_leukemia.pdf (accessed September 1, 2010).

Howell, R. R. 2005. Letter to Michael Leavitt, Secretary, U.S. Department of Health and Human Services, RE: Recommendations to the Secretary of Health and Human Services from the Advisory Committee on Heritable Disorders in Newborns and Children. September 9. http://www.hrsa.gov/heritabledisorderscommittee/correspondence/sep2005letter.htm (accessed August 19, 2010).

Huang, A., and G. Javitt. 2008. FDA Regulation of Genetic Tests. http://www.dnapolicy.org/images/issuebriefpdfs/FDA_Regulation_of_Genetic_Test_Issue_Brief.pdf (accessed August 5, 2010).

Hubacher, D. 2002. The checkered history and bright future of intrauterine contraception in the United States. Perspectives on Sexual and Reproductive Health 34(2):98-103.

Hunter, J., and S. Stephens. 2010. Is open innovation the way forward for big pharma? Nature Reviews Drug Discovery 9:87-88.

Hyde, J. 2006. Memorandum to Julie Beitz, Office of Drug Evaluation 3, Center for Drug Evaluation and Research, FDA, RE: Summary Supervisory Review of BLA/STN, 125151/0 [Elaprase] Idursulfase for Mucopolysaccharidosis Type II (Hunter Syndrome). Silver Spring, MD. July 24.

Hyman, S. E. 2008. A glimmer of light for neuropsychiatric disorders. Nature 455(7215): 890-893.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

ICMJE (International Committee of Medical Journal Editors). 2009. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Publishing and Editorial Issues Related to Publication in Biomedical Journals: Obligation to Register Clinical Trials. http://www.icmje.org/publishing_10register.html (accessed August 13, 2010).

IFOPA (International Fibrodysplasia Ossificans Progressiva Association). 2009. FOP FAQ. http://www.ifopa.org/index.php?option=com_content&view=article&id=24&Itemid=156&lang=en (accessed August 5, 2010).

Imel, E. A., L. A. DiMeglio, S. L. Hui, T. O. Carpenter, and M. J. Econs. 2010. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. Journal of Clinical Endocrinology and Metabolism 95(4):1846-1850.

Interagency Task Force to the Secretary of Health, Education, and Welfare. 1979. Significant Drugs of Limited Commercial Value. Rockville, MD: Food and Drug Administration.

IOM (Institute of Medicine). 1991. The Artificial Heart: Prototypes, Policies, and Patients. Washington, DC: National Academy Press.

IOM. 2001. Tuberculosis in the Workplace. Washington, DC: National Academy Press.

IOM. 2004. Improving Medical Education: Enhancing the Behavioral and Social Science Content of Medical School Curricula. Washington, DC: The National Academies Press.

IOM. 2006. Safe Medical Devices for Children, edited by M. J. Field and H. Tilson. Washington, DC: The National Academies Press.

IOM. 2007. Future of Disability in America. Washington, DC: The National Academies Press.

IOM. 2008. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press.

IOM. 2009a. Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities. Washington, DC: The National Academies Press.

IOM. 2009b. Venture Philanthropy Strategies to Support Translational Research. Workshop Summary. Washington, DC: The National Academies Press.

IOM. 2010a. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, DC: The National Academies Press.

IOM. 2010b. Extending the Spectrum of Precompetitive Collaboration in Oncology Research. Workshop Summary. Washington, DC: The National Academies Press.

IOWH (Institute for OneWorld Health). 2004. $42.6 Million Five-Year Grant From Gates Foundation for Antimalarial Drug Brings Together Unique Collaboration of Biotech, Academia and Nonprofit Pharma (press release). December 13. http://www.oneworldhealth.org/documents/DP_%20Malaria%20Release%20121304.pdf (accessed September 7, 2010).

Iribarne, A. 2003. Orphan diseases and adoptive initiatives. Journal of the American Medical Association 290:116.

IRSF (International Rett Syndrome Foundation). 2008. Rett Syndrome Research Landscape. http://www.rettsyndrome.org/dmdocuments/IRSF_LANDSCAPE%20ANALYSIS_2008-1.pdf (accessed August 20, 2010).

Javitt, G. H. 2007. In search of a coherent framework: options for FDA oversight of genetic tests. Food and Drug Law Journal 62(4):617-652.

Johnston, J. J., J. K. Teer, P. F. Cherukuri, N. F. Hansen, S. K. Loftus, NIH Intramural Sequencing Center, K. Chong, et al. 2010. Massively parallel sequencing of exons on the x chromosome identifies rbm10 as the gene that causes a syndromic form of cleft palate. American Journal of Human Genetics 86(5):743-748.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Jones, J. A., F. G. Spinale, and J. S. Ikonomidis. 2009. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. Journal of Vascular Research 46(2):119-137. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645475/ (accessed August 11, 2010).

Jones, M. 2010. FDA Joins NIH and EPA in Tox21 Effort. July 20. http://www.genomeweb.com/fda-joins-nih-and-epa-tox21-effort (accessed August 20, 2010).

JPMA (Japan Pharmaceutical Manufacturers Association, E. R. I. T. F). 2008. Pharmaceutical administration and regulations in Japan. Information in English on Japan Regulatory Affairs. http://www.nihs.go.jp/mhlw/yakuji/yakuji-e0808.pdf (accessed August 5, 2010).

Justice, R. 2007. Approval Letter to Bayer Pharmaceuticals Corporation for New or Modified Indication Application Number 021923 [Nexavarto]. Rockville, MD. November 16. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021923s004,s005,s006,s007.pdf (accessed August 19, 2010).

Kaback, M., J. Lim-Steele, D. Dabholkar, D. Brown, N. Levy, K. Zeiger, and the International TSD Data Collection Network. 1993. Tay-Sachs disease—carrier screening, prenatal diagnosis, and the molecular era: an international perspective, 1970 to 1993. Journal of the American Medical Association 270(19):2307-2315.

Kakkis, E. 2010. Accelerating development of treatments for rare diseases. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4.

Kaplan, A. V., D. S. Baim, J. J. Smith, D. A. Feigal, M. Simons, D. Jefferys, T. J. Fogarty, et al. 2004. Medical device development: from prototype to regulatory approval. Circulation 109(25):3068-3072.

Kaplan, A. V., E. D. Harvey, R. E. Kuntz, H. Shiran, J. F. Robb, and P. Fitzgerald. 2005. Humanitarian use devices/humanitarian device exemptions in cardiovascular medicine. Circulation 112(18):2883-2886.

Karst, K. R. 2009a. Outstanding Pre-FDAAA Citizen Petition Causes FDA to Rule Against 180-Day Exclusivity Forfeiture for Generic Skelaxin. http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2010/05/outstanding-prefdaaa-citizen-petition-causes-fda-to-rule-against-180day-exclusivity-forfeiture-for-g.html (accessed August 5 2010).

Karst, K. R. 2009b. The rarely used “cost recovery” path to orphan drug designation and approval. FDA Law Blog. http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2009/02/the-rarely-used-cost-recovery-path-to-orphan-drug-designation-and-approval.html (accessed July 15, 2010).

Karst, K. R. 2009c. The unusual case of the “MC-to-PC” orphan drug designation/approval. FDA Law Blog. http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2009/01/the-unusual-case-of-the-mctopc-orphan-drug-designationapproval-.html (accessed August 5, 2010).

Karst, K. R. 2010. FDA issues NOOH proposing to withdraw all midodrine HCl approvals. FDA Law Blog. http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2010/08/fda-issues-nooh-proposing-to-withdraw-all-mididrine-hcl-approvals.html (accessed September 1, 2010).

Kay, M. A., C. N. Landen, S. R. Rothenberg, L. A. Taylor, F. Leland, S. Wiehle, B. Fang, et al. 1994. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proceedings of the National Academy of Sciences 91(6):2353-2357.

Kelley, S. L. 2009. MMRF and MMRC collaborative research model for a rare disease. Presentation on behalf of the Multiple Myeloma Research Foundation and the Multiple Myeloma Research Consortium to the IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. November 23.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Kelly, A. M., B. Kratz, M. Bielski, and P. M. Rinehart. 2002. Implementing transitions for youth with complex chronic conditions using the medical home model. Pediatrics 110(6):1322-1327.

Kelly, P. F., S. Radtke, C. Von Kalle, B. Balcik, K. Bohn, R. Mueller, T. Schuesler, et al. 2007. Stem cell collection and gene transfer in Fanconi anemia. Molecular Therapy 15(1):211-219.

Kesselheim, A. S., and M. M. Mello. 2010. Gene patenting—is the pendulum swinging back? New England Journal of Medicine 362(20):1855-1858.

Kesselheim, A. S., and D. H. Solomon. 2010. Incentives for drug development—the curious case of colchicine. New England Journal of Medicine 362(22):2045-2047.

KFF (Kaiser Family Foundation). 2008. [Medicaid] Benefits by Service: Prescription Drugs (October 2008). http://medicaidbenefits.kff.org/service.jsp?gr=off&nt=on&so=0&tg=0&yr=4&cat=5&sv=32 (accessed August 5, 2010).

KFF. 2009a. Fact Sheet: Medicare Advantage. http://www.kff.org/medicare/upload/2052-13.pdf (accessed August 5, 2010).

KFF. 2009b. Fact Sheet: The Medicare Prescription Drug Benefit. http://www.kff.org/medicare/upload/7044-10.pdf (accessed August 5, 2010).

KFF. 2009c. Employer Health Benefits: 2009 Annual Survey. http://ehbs.kff.org/pdf/2009/7936.pdf (accessed August 5, 2010).

KFF. 2009d. Medicare Part D 2010 Data Spotlight: Benefit Design and Cost Sharing. http://www.kff.org/medicare/upload/8033.pdf (accessed August 5, 2010).

KFF-SHF (Kaiser Family Foundation, statehealthfacts.org). 2010. Health Insurance Coverage of Nonelderly 0-64, States (2007-2008), U.S. (2008). http://www.statehealthfacts.org/comparetable.jsp?ind=126&cat=3 (accessed August 5, 2010).

Kleta, R., and W. A. Gahl. 2004. Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opinion on Pharmacotherapy 5(11):2255-2262.

Kocs, D., and A. M. Fendrick. 2003. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. American Journal of Managed Care 9(5):393-400.

Kramer, D. L. B., E. Mallis, B. D. Zuckerman, B. A. Zimmerman, and W. H. Maisel. 2010. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. American Journal of Therapeutics 17(1):2-7.

Kuehn, B. M. 2010. Strategy reveals rare disease genes. Journal of the American Medical Association 303(24):2463.

Lacro, R. V., H. C. Gietz, L. M. Wruck, T. J. Bradley, S. D. Colan, R. B. Devereux, G. L. Klein, et al. 2007. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. American Heart Journal 154(4):624-631.

Laessig, K. 2009. Presentation at Division of Anti-infective Drugs Advisory Committee Meeting, Washington, DC. December 10. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM197009.pdf (accessed August 5, 2010).

Lai, K., M. Tang, X. Yin, H. Klapper, K. Wierenga, and L. J. Elsas. 2008. ARHI: a new target of galactose toxicity in classic galactosemia. Bioscience Hypotheses 1(5):263-271.

LeBowitz, J. H. 2005. A breach in the blood-brain barrier. Proceedings of the National Academy of Sciences 102(41):14485-14486. http://www.pnas.org/content/102/41/14485.full%5d.

LeMasurier, J. D., and B. Edgar. 2009. MIPPA: first broad changes to Medicare Part D Plan operations. American Health & Drug Benefits 2(3):111-118. http://www.ahdbonline.com/docs/april_09/LeMasurier_AprilMay09.pdf (accessed August 5, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Lerner, B. H. 2009. When diseases disappear: the case of familial dysautonomia. New England Journal of Medicine 361(17):1622-1625.

Lewis, D. 2010. Rare diseases update. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4.

LGDA (Lymphangiomatosis & Gorham’s Disease Alliance). 2009. About Gorham’s Disease. http://lgdalliance.org/en/aboutGorhamsDisease/Default.aspx (accessed August 5, 2010).

Li, Y., K. Brockmann, F. Turecek, C. R. Scott, and M. H. Gelb. 2004. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clinical Chemistry 50(3):638-640.

Library of Congress. 1994. Country Studies: Japan. http://memory.loc.gov/frd/cs/jptoc.html (accessed August 5, 2010).

Lifton, R. P. 2010. Individual genomes on the horizon. New England Journal of Medicine 362(13):1235-1236.

Lifton R. P., A. G. Gharavi, and D. S. Geller. 2001. Molecular mechanisms of human hypertension. Cell 104(4):545-556.

Lim-Melia, E. R., and D. F. Kronn. 2009. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatric Annals 38(8):448-455.

Linehan, J. H., M. E. Paté-Cornell, P. G. Yock, and J. B. Pietzsch. 2007. Study on Medical Device Development Models Final Report. Stanford, CA: Stanford University.

Liu L., M. Krailo, G. H. Reaman, and L. Bernstein. 2003. Childhood cancer patients’ access to cooperative group cancer programs: a population-based study. Cancer 97:1339-1345.

Llovet, J. M., S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.-F. Blanc, and A. C. de Oliveira. 2008. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 359(4):378-390.

Lloyd, C. 2004. Letter to Carol Benson, Center for Devices and Radiological Health RE: de nova classification of NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit, Model MS-8970. Dockets Management, Docket # 2004P-0419. June 30. http://www.fda.gov/ohrms/dockets/dailys/04/sep04/091404/04p-0419-cp00001-vol1.pdf (accessed August 19, 2010).

Long, F. 2008. When the gut talks to bone. Cell 135(5):795-796.

Lu, M., D. Z. Vasavada, and C. Tanner. 2009. Lemierre syndrome following oropharyngeal infection: a case series. Journal of the American Board of Family Medicine 22(1):79-83.

Lupski, J. R., J. G. Reid, C. Gonzaga-Jauregui, D. Rio Deiros, D. C. Y. Chen, L. Nazareth, M. Bainbridge, et al. 2010. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. New England Journal of Medicine 362(13):1181-1191.

Madsen, C. A. 2004. Herceptin (Trastuzumab) a real world example of pharmacogenomics—maximizing patient benefit. WeSRCH Medtech. July 29. http://medical.wesrch.com/pdfME1XXFF7UAXKL (accessed September 22, 2010).

Maegawa, G. H. B., and R. D. Steiner. In press. Treating genetic disorders. In Medical Genetics and Pediatric Practice: A Handbook, edited by R. A. Saul. Elk Grove Village, IL: American Academy of Pediatrics.

Maestri, N. E., and T. H. Beaty. 1992. Predictions of a 2-locus model for disease heterogeneity: application to adrenoleukodystrophy. American Journal of Medical Genetics 44(5):576-582.

Maher, E. R., L. Iselius, J. R. Yates, M. Littler, C. Benjamin, R. Harris, J. Sampson, et al. 1991. Von Hippel-Lindau disease: a genetic study. Journal of Medical Genetics 28:443-447.

Majumdar, S. R. 2009. Cost sharing and the initiation of drug therapy for the chronically ill—invited commentary. Archives of Internal Medicine 169(8):748-749.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Maloney, P. 2010. Laboratory regulation under the Clinical Laboratory Improvement Amendments of 1988 and state laws. In In Vitro Diagnostics: The Complete Regulatory Guide, edited by S. D. Danzis and E. J. Flannery. Washington, DC: The Food and Drug Law Institute.

Manning, E., S. Pham, S. Li, R. I. Vazquez-Padron, J. Mathew, P. Ruiz, and S. K. Salgar. 2010. Interleukin-10 delivery via mesenchymal stem cells: a novel gene therapy approach to prevent lung ischemia-reperfusion injury. Human Gene Therapy 21(6):713-727.

Mansfield, E., and Ž. Težak. 2010. FDA regulation of genetic testing. In In Vitro Diagnostics: The Complete Regulatory Guide, edited by S. D. Danzis and E. J. Flannery. Washington, DC: The Food and Drug Law Institute.

March of Dimes. 2010. Fact Sheet: Newborn Screening. http://www.marchofdimes.com/professionals/14332_1200.asp (accessed August 5, 2010).

Marcus, A. D. 2010a. My data, your data, our data. Wall Street Journal, April 13. http://online.wsj.com/article/SB10001424052748703625304575116512173339800.html#printMode (accessed August 5, 2010).

Marcus, A. D. 2010b. NIH takes on new role in fight against rare diseases. Wall Street Journal, July 24. http://online.wsj.com/article/NA_WSJ_PUB:SB10001424052748704249004575385363395104490.html#articleTabs%3Darticle (accessed August 20, 2010).

Marcus, A. D. 2010c. Push to cure rare diseases. Wall Street Journal, March 10. http://www.kgi.edu/Documents/In_the_news/FDA%20Pushes%20for%20Cures%20for%20Rare%20Diseases.pdf (accessed August 27, 2010).

Maron, B. J., and N. A. M. Estes. 2010. Commotio cordis. New England Journal of Medicine 362(10):917-927.

Maschke, K. J. 2009. Disputes over research with residual newborn screening blood specimens. Hastings Center Report 40(2).

Masiello, S. A., and J. S. Epstein. 2003. Correction Letter to Stephen Arnon, Senior Director, Regulatory Affairs, Cato Research, Inc. for October 23, 2003, Approval letter BabyBIG. December 9. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117164.htm (accessed August 19, 2010).

McCabe, M. T., J. C. Brandes, and P. M. Vertino. 2009. Cancer DNA methylation: molecular mechanisms and clinical implications. Clinical Cancer Research 15:3927-3937.

McCarty, M., and K. Young. 2007. FDA to push ahead with assay guidance despite opposition. In Advances in Diagnostics & Imaging 2:15-19. http://www.medicaldevicedaily.com/img/S07414SamplePages.pdf (accessed August 5, 2010).

Medline Plus. 2008. Beriberi. July 12. http://www.nlm.nih.gov/medlineplus/ency/article/000339.htm (accessed August 5, 2010).

MedPAC (Medicare Payment Advisory Commission). 2007. Report to the Congress: Impact of Changes in Medicare Payments for Part B Drugs. http://www.medpac.gov/documents/Jan07_PartB_mandated_report.pdf (accessed August 5, 2010).

MedPAC. 2008. Outpatient Hospital Services Payment System. http://www.medpac.gov/documents/MedPAC_Payment_Basics_08_OPD.pdf (accessed August 5, 2010).

MedPAC. 2009. Medicare payment systems and follow-on biologics. Report to the Congress: Improving Incentives in the Medicare Program. http://www.medpac.gov/chapters/Jun09_Ch05.pdf (accessed August 5, 2010).

MedPAC. 2010a. Chapter 5: Status report on Part D. In Report to the Congress: Medicare Payment Policy. http://www.medpac.gov/chapters/Mar10_Ch05.pdf (accessed August 5, 2010).

MedPAC. 2010b. Chapter 2: Improving traditional Medicare’s benefit design. In Report to the Congress: Aligning Incentives in Medicare. http://www.medpac.gov/chapters/Jun10_Ch02.pdf (accessed August 5, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Medtronic, Inc. 2009. Melody®Transcatheter Pulmonary Valve Ensemble®Transcatheter Valve Delivery System. http://wwwp.medtronic.com/Newsroom/LinkedItemDetails.do?itemId=1260978939170&itemType=fact_sheet&lang=en_US (accessed August 5, 2010).

Medtronic, Inc. 2010. First Publication of Data from Pivotal Clinical Trial for Medtronic Deep Brain Stimulation Therapy for Epilepsy Published Today in Epilepsia. http://wwwp.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1268914059828 (accessed August 5, 2010).

Mehta, S., T. G. Myers, J. H. Lonner, G. R. Huffman, and B. J. Sennett. 2007. The ethics of sham surgery in clinical orthopaedic research. Journal of Bone and Joint Surgery 89(7):1650-1653.

Melese, T., S. M. Lin, J. L. Chang, and N. H. Cohen. 2009. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nature Medicine 15:502-507.

Merkens, L. S., C. Wassif, K. Healy, A. S. Pappu, A. E. DeBarber, J. A. Penfield, R. A. Lindsay, et al. 2009. Smith-Lemli-Opitz syndrome and inborn errors of cholesterol synthesis: summary of the 2007 SLOS/RSH foundation scientific conference sponsored by the National Institutes of Health. Genetic Medicine 11(5):359-364.

Meyers, A., and M. L. Di Paola. 2003. The orphan medicinal products: an international challenge. Minerva Biotechnologica. http://www.rarediseases.org/news/images/minerva_biotech_orphmed_article_11504.jpg (accessed August 5, 2010).

Mikhail, I. S. 2005. Design issues in the study of rare cancers. Presented at the 2nd NCI Epidemiology Leadership Workshop: Understudied Rare Cancers, Boston, MA. http://epi.grants.cancer.gov/documents/Conference2/slides/Mikhail.pdf (accessed September 1, 2010).

Miller, F. G. 2003. Sham surgery: an ethical analysis. American Journal of Bioethics 3(4): 41-48.

Milne, C. P. 2002. Orphan products—pain relief for clinical development headaches. Nature Biotechnology 20(8):780-784.

Mingozzi, F., and K. A. High. 2009. Gateway to the diseased brain. Nature Medicine 15:1123-1124. http://www.nature.com/nm/journal/v15/n10/abs/nm1009-1123.html (accessed August 12, 2010).

Mitka, M. 2009. Off-label cancer drug compendia found outdated and incomplete. Journal of the American Medical Association 301(16):1645-1646.

Mitsumoto, J., E. R. Dorsey, C. A. Beck, K. Kieburtz, and R. C. Griggs. 2009. Pivotal studies of orphan drugs approved for neurological diseases. Annals of Neurology 66(2):184-190.

Mizrachi, I. 2007. GenBank: The Nucleotide Sequence Database. In The NCBI Handbook, edited by J. McEntyre and J. Ostell. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=handbook&part=ch1 (accessed August 22, 2010).

MMF (Minnesota Medical Foundation). 2007. Setting the Pace: What Do You Get When You Combine a Heart Surgeon and an Electrical Engineer? http://www.mmf.umn.edu/bul-letin/2007/fall/lookback/index.cfm (accessed August 5, 2010).

MMV (Medicines for Malaria Venture). 2002. Annual Report. http://www.mmv.org/newsroom/publications/annual-report-2002 (accessed August 5, 2010).

MMV. 2003. Annual Report. http://www.mmv.org/newsroom/publications/annual-report-2003 (accessed August 5, 2010).

Monroe, C. D., L. Potter, M. Millares, A. Barrueta, and R. Wagner. 2006. Kaiser Permanente’s evaluation and management of biotech drugs: assessing, measuring, and affecting use. Health Affairs 25(5):1340-1346.

Moore, J. H., and M. D. Ritchie. 2004. The challenges of whole-genome approaches to common diseases. Journal of the American Medical Association 291(13):1642-1643.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Moran, M. 2005. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Medicine 2(9):e302. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1198042/ (accessed December 1, 2010).

Moran, M., Ropars A-L., Guzman J., Diaz J., and Garrison C. 2004. The New Landscape of Neglected Disease Drug Development. The Wellcome Trust and London School of Economics and Political Sciences. London: The Wellcome Trust Publications Department.

Morel, C. M. 2000. Reaching maturity—25 years of the TDR. Parasitology Today 16(12):522-528.

Moseley, J. B., K. O’Malley, N. J. Petersen, T. J. Menke, B. A. Brody, D. H. Kuykendall, J. C. Hollingsworth, et al. 2002. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. New England Journal of Medicine 347(2):81-88.

Moser, A. B., S. J. Steinberg, and G. V. Raymond. 2009. X-linked adrenoleukodystrophy.2009. X-linked adrenoleukodystrophy. Gene Reviews. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=x-ald (accessed August 5, 2010).

Mossinghoff, G. J. 1999. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food and Drug Law Journal 54(2):187-194.

Moyer, V. A., N. Calonge, S. M. Teutsch, and J. R. Botkin. 2008. Expanding newborn screening: process, policy, and priorities. Hastings Center Report 38(3):32-39.

MRF (Myelin Research Foundation). 2010. Comparisons Between ARC vs. Traditional Research. http://www.myelinrepair.org/research_model/arc_vs_traditional_research.shtml (accessed August 5, 2010).

Munos, B. 2009. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8(12):959-968.

Munos, B. 2010. Can open-source drug R&D repower pharmaceutical innovation? Clinical Pharmacology and Therapeutics 87:534-536.

Nathan, D. 2009. Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases. Genome Medicine 1(114).

Nathan, D. G., and S. H. Orkin. 2009. Musings on genome medicine: gene therapy. Genome Medicine 1(38).

NAS (National Academy of Sciences). 2003. Materials and Society: From Research to Manufacturing—Report of a Workshop. Washington, DC: The National Academies Press.

NCCAM (National Center for Complementary and Alternative Medicine). 2008. Milk Thistle. http://nccam.nih.gov/health/milkthistle/ataglance.htm (accessed August 5, 2010).

NCBI (National Center for Biotechnology Information). 2009. GENETests: Growth of Laboratory Directory. http://www.ncbi.nlm.nih.gov/projects/GeneTests/static/whatsnew/labdirgrowth.shtml (accessed August 4, 2010).

NCBI. 2010. Questions and Answers: Genetic Testing Registry. http://www.ncbi.nlm.nih.gov/gtr/qa/ (accessed August 4, 2010).

NCI (National Cancer Institute). 2009a. Adult Brain Tumors Treatment (PDQ®). http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/HealthProfessional/page10 (accessed August 5, 2010).

NCI. 2009b. States That Require Health Plans to Cover Patient Care Costs in Clinical Trials. http://www.cancer.gov/clinicaltrials/developments/laws-about-clinical-trial-costs (accessed August 5, 2010).

NCI. 2009c. Table 1.4: Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival Rates by Primary Cancer Site, Sex and Time Period. http://www.seer.cancer.gov/csr/1975_2006/results_merged/topic_survival.pdf (accessed August 5, 2010).

NCOD (National Commission on Orphan Diseases). 1989. Report of the National Commission on Orphan Diseases. Rockville, MD: Public Health Service, U.S. Department of Health and Human Services.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

NDRI (National Disease Research Interchange). 2003. The Genetics of Rare Disease: Window to Common Disorders (conference). Washington, DC. March 23.

NDRI. 2010. NDRI Initiatives: Rare Diseases. http://www.ndriresource.org/NDRI_Initiatives/Rare_Disease/30/ (accessed August 4, 2010).

Neschadim, A., J. A. McCart, A. Keating, and J. A. Medin. 2007. A roadmap to safe, efficient, and stable lentivirus-medicated gene therapy with hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 13(12):1407-1416.

Newhouse, J. P., and the Insurance Experiment Group. 1993. Free for All? Lessons from the RAND Health Insurance Experiment. Cambridge, MA: Harvard University Press.

Ng, S. B., K. J. Buckingham, C. Lee, A. W. Bigham, H. K. Tabor, K. M. Dent, C. D. Huff, et al. 2009. Exome sequencing identifies the cause of a Mendelian disorder. Nature Genetics 42(1):30-35.

NHGRI (National Human Genome Research Institute). 2009. Learning About Gaucher Disease. http://www.genome.gov/25521505 (accessed August 4, 2010).

NHLBI (National Heart, Lung, and Blood Institute). 2000. Expert Panel Review of the NHLBI Total Artificial Heart (TAH) Program June 1998-November 1999. http://www.nhlbi.nih.gov/resources/docs/tahrpt.pdf (accessed August 4, 2010).

NHLBI. 2008a. NHLBI Working Group Report: Computational Models for Analyzing Genotype-Phenotype Associations in Rare Diseases. http://www.nhlbi.nih.gov/meetings/workshops/gpa_rarediseases.htm (accessed August 4, 2010).

NHLBI. 2008b. What Is LAM? http://www.nhlbi.nih.gov/health/dci/Diseases/lam/lam_all.html (accessed August 4, 2010).

NHLBI. 2009. What Is Aplastic Anemia? http://www.nhlbi.nih.gov/health/dci/Diseases/aplastic/aplastic_whatis.html (accessed August 4, 2010).

NHLBI. 2010. Sickle Cell Disease Awareness and Education Strategy Development Workshop Report. http://www.nhlbi.nih.gov/meetings/workshops/Sickle_Cell_Disease_Workshop.pdf (accessed August 20, 2010).

NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases). 2010. Polymyalgia Rheumatica and Giant Cell Arteritis. http://www.niams.nih.gov/Health_Info/Polymyalgia/default.asp (accessed August 4, 2010).

NIBIB (National Institute of Biomedical Imaging and Bioengineering). 2009. About NIBIB: Mission & History. http://www.nibib.nih.gov/About/MissionHistory (accessed August 4, 2010).

NICHD (National Institute of Child Health and Human Development). 2009. NIH Newborn Screening Research Program Named in Memory of Hunter Kelly. http://www.nichd.nih.gov/news/releases/101909-Hunter-Kelly.cfm (accessed August 4, 2010).

NIH (National Institutes of Health). 2002. Report on Steps to Coordinate Rare Diseases Research Programs. http://rarediseases.info.nih.gov/Wrapper.aspx?src=asp/html/reports/fy1999/SEP.html (accessed October 11, 2010).

NIH. 2003. Final NIH statement on sharing research data. Notice NOT-OD-03-032. February 26. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html (accessed August 24, 2010).

NIH. 2007. NIH Policy Manual: 1167—Public-Private Partnerships. September 25. http://oma.od.nih.gov/manualchapters/management/1167/ (accessed August 20, 2010).

NIH. 2008. Nocardia Infection. http://www.nlm.nih.gov/medlineplus/ency/article/000679.htm (accessed August 4, 2010).

NIH. 2009a. NIH Announces Expansion of Rare Diseases Clinical Research Network. http://www.nih.gov/news/health/oct2009/od-05.htm (accessed August 4, 2010).

NIH. 2009b. NIH Announces New Program to Develop Therapeutics for Rare and Neglected Diseases. http://rarediseases.info.nih.gov/files/TRND%20Press%20Release.pdf (accessed August 4, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

NIH. 2010a. The Cancer Genome Atlas Identifies Distinct Subtypes of Deadly Brain Cancer That May Lead to New Treatment Strategies (news release). http://cancergenome.nih.gov/media/glioblastoma4subtypes.asp (accessed August 4, 2010).

NIH. 2010b. Advancing Regulatory Science Through Novel Research and Science-Based Technologies (U01). Request for Applications Number: RFA-RM-10-006. http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-10-006.html (accessed August 4, 2010).

Nijsten, T., and P. R. Bergstresser. 2010. Patient advocacy groups: let’s stick together. Journal of Investigative Dermatology 130(7):1757-1759. http://www.nature.com/jid/journal/v130/n7/pdf/jid2010131a.pdf (accessed September 8, 2010).

NNSGRC (National Newborn Screening and Genetics Resource Center). 2010. National Newborn Screening Status Report. http://genes-r-us.uthscsa.edu/nbsdisorders.pdf (accessed August 4, 2010).

NORD (National Organization for Rare Disorders). 2003. NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott Williams & Wilkins.

NORD. 2007. Testimony Before the Social Security Administration Public Hearing on Compassionate Allowances. Washington, DC. December 4. http://www.ssa.gov/compassionateallowances/NORDTestimonyCompassionateAllowances120407.pdf (accessed August 4, 2010).

NORD. 2010. NORD Reports Progress in Appropriations Bill. http://www.rarediseases.org/news/Appropriations_Progress (accessed August 4, 2010).

NRC (National Research Council). 2000. Bioinformatics: Converting Data to Knowledge: Workshop Summary. Washington, DC: National Academy Press.

NRC. 2006. Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation and Public Health. Washington, DC: The National Academies Press.

NRC. 2007. The New Science of Metagenomics: Revealing the Secrets of Our Microbial Planet. Washington, DC: The National Academies Press.

NRC. 2009. A New Biology for the 21st Century: Ensuring the United States Leads the Coming Biology Revolution. Washington, DC: The National Academies Press.

NTP (National Toxicology Program). 2004. Technical Report on the Toxicology and Carcinogenesis Studies of Elmiron. http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr512.pdf (accessed August 13, 2010).

Nussbaum, R. L., R. R. McInnes, and H. F. Willard. 2004. Thompson & Thompson Genetics in Medicine, 7th Edition. Philadelphia, PA: W.B. Saunders Company.

Nutt, B. 2007. From the Other Side of the Stethoscope. http://www.thelamfoundation.org/patients/living-with-lam/patient-storiesAll.html/#Nutt (accessed August 4, 2010).

Nwaka, S., and R. G. Ridley. 2003. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature Reviews Drug Discovery 2:919-928.

Öfverholm, A., E. Arkblad, S. Skrtic, P. Albertsson, E. Shubbar, and C. Enerbäck. 2010. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clinical Biochemistry 43(3):331-334.

OHRP (Office of Human Research Protections). 2008. OHRP Research Involving Children Frequently Asked Questions. http://www.hhs.gov/ohrp/researchfaq.html (accessed August 4, 2010).

OIG (Office of the Inspector General, DHHS). 2001a. Medicare Hospital Prospective Payment System: How DRG Rates Are Calculated and Updated. http://oig.hhs.gov/oei/reports/oei-09-00-00200.pdf (accessed August 4, 2010).

OIG. 2001b. The Orphan Drug Act Implementation and Impact. http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf (accessed August 4, 2010).

OIG. Undated. Rare Diseases and Related Terms. http://rarediseases.info.nih.gov/RareDiseaseList.aspx (accessed August 4, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

OOPD (Office of Orphan Product Development, FDA). 2009. Recipients of the FY09 Pediatric Device Consortia Grant Program Awards. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/WhomtoContactaboutOrphanProductDevelopment/ucm184125.htm (accessed August 4, 2010).

OOPD. 2010. New Resource for Drug Developers: The Rare Disease Repurposing Database (RDRD). http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm216147.htm (accessed September 24, 2010).

ORDR (Office of Rare Diseases Research, NIH). 2009. Office of Rare Diseases Research (ORDR) Brochure. http://rarediseases.info.nih.gov/Wrapper.aspx?src=asp/resources/ord_brochure.html (accessed August 4, 2010).

Orphanet. 2009. Prevalence of Rare Diseases. Orphanet Report Series, No. 1, November. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf (this link is to a more recent version of the report than was used by the committee).

Orphanet. Undated a. About Orphanet: Mission. http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanet.php?lng=EN (accessed August 4, 2010).

Orphanet. Undated b. About Rare Diseases. http://www.orpha.net/consor/cgi-bin/Education_AboutRareDiseases.php?lng=EN (accessed August 4, 2010).

Outterson, K., and A. S. Kesselheim. 2009. How Medicare could get better prices on prescription drugs. Health Affairs 28(5):w832-841.

Pannicke, U., M. Honig, I. Hess, C. Friesen, K. Holzmann, E. M. Rump, T. F. Barth, et al. 2009. Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nature Genetics 41(1):101-105.

Pariser, A. 2010. FDA regulation and review of small clinical trials. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4.

Patel, C. J., J. Bhattacharya, and A. J. Butte. 2010. An environment-wide association study (EWAS) on type 2 diabetes mellitus. Public Library of Science ONE 5(5):e10746.

Patterson, M. 2008. Niemann-Pick Disease Type C. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=npc (accessed August 3, 2010).

Pfizer. 2010. Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® (press release). http://media.pfizer.com/files/news/press_releases/2010/mylotarg_discontinuation_062110.pdf (accessed August 3, 2010).

Pharmaceutical Forum, E.C. 2008. Improving access to orphan medicines for all affected EU citizens. Reference Document 3 in High Level Pharmaceutical Forum 2005-2008 Final Report. http://ec.europa.eu/pharmaforum/docs/pricing_orphans_en.pdf (accessed August 3, 2010).

PhRMA (Pharmaceutical Research and Manufacturers of America). 2007. Drug Discovery and Development: Understanding the R & D Process. Washington, DC. http://www.phrma.org/files/attachments/RD%20Brochure%20022307.pdf (accessed August 27, 2010).

Pietzsch, J. B., L. A. Shluzas, M. E. Paté-Cornell, P. G. Yock, and J. H. Linehan. 2009. Stage-gate process for the development of medical devices. Journal of Medical Devices 3(2).

Pion, G., and M. Ionescu-Pioggia. 2003. Bridging postdoctoral training and a faculty position: initial outcomes of the Burroughs Wellcome Fund Career Awards in the Biomedical Sciences. Academic Medicine 78(2):177-186.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

PMC (Personalized Medicine Coalition). 2009. Comments on Development of Companion Diagnostics and the April 2005 Food and Drug Administration (“FDA”) Drug-Diagnostic Co-development Concept Paper. December 9. http://www.personalizedmedicinecoalition.org/sites/default/files/files/FDA%20CoDevelopment%20FINAL%20Version%20PDF.pdf (accessed August 4, 2010)

Pober, B. R. 2010. Williams-Beuren syndrome. New England Journal of Medicine 362(3): 239-252.

Pollack, A. 2008. Cutting dosage of costly drug spurs a debate. New York Times, March 16.

Pollack, A. 2009. Pfizer deal signals a move into treating rare diseases. New York Times, December 2. http://query.nytimes.com/gst/fullpage.html?res=9C0DE5D8153BF931A35751C1A96F9C8B63&sec=&spon=&pagewanted=print (accessed August 3, 2010).

Pollack, A. 2010. After gene patent is invalidated, taking stock. New York Times, March 30. http://www.nytimes.com/2010/03/31/business/31gene.html (accessed August 20, 2010).

PRF (Progeria Research Foundation). 2008. The Progeria Research Foundation Timeline. http://progeriaresearch.org/assets/files/pdf/Timeline%20Nov%2007.pdf (accessed August 3, 2010).

Prosser, L. A., C. Y. Kong, D. Rusinak, and S. L. Waisbren. 2010. Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics 125:e286-e294.

Q1Medicare.com. 2009. PDP—Facts: 2010 Medicare Part D Plan Statistics—Region (State) and National. http://www.q1medicare.com/PartD-MedicarePartDPlanStatisticsState.php?crit=National (accessed August 3, 2010).

Radcliffe, S. 2009. BIO (Biotechnology Industry Organization). Statement to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. November 23. http://www.bio.org/reg/20091123.pdf (accessed August 2, 2010).

Radley, D. C., S. N. Finkelstein, and R. S. Stafford. 2006. Off-label prescribing among office-based physicians. Archives of Internal Medicine 166(9):1021-1026.

Rai, A. K., J. H. Reichman, P. F. Uhlir, and C. Crossman. 2008. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery. Yale Journal of Health Policy, Law, and Ethics VIII(I):52-89. http://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=2329&context=faculty_scholarship (accessed August 3, 2010).

Rappaport, B. 2010. Division director summary basis for recommendation of approval action. Summary Review, Application Number 125338 [Xiaflex]. February 1. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125338s000SumR.pdf (accessed August 3, 2010).

Ray, T. 2010. FDA Chief Commits to Completing Rx/Dx Codevelopment Guidance This Year, Improving Regulatory Science. http://www.genomeweb.com/dxpgx/fda-chief-commits-completing-rxdx-codevelopment-guidance-year-improving-regulato (accessed August 3, 2010).

RegenceRx. 2010. Off-Label Use of FDA-Approved Drugs. http://blue.regence.com/trgmedpol/drugs/dru031.pdf (accessed August 3, 2010).

Reich, M. R. 2000. The global drug gap. Science 287(5460):1979-1981.

Reichert, J. M., C. J. Rosensweig, L. B. Faden, and M. C. Dewitz. 2005. Monoclonal antibody successes in the clinic. Nature Biotechnology 23:1073-1078.

Reiffen, D., and M. R. Ward. 2005. Generic drug industry dynamics. Review of Economics and Statistics 87(1):37-49.

Richey, E. A., E. A. Lyons, J. R. Nebeker, V. Shankaran, J. M. McKoy, T. H. Luu, N. Nonzee, et al. 2009. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? Journal of Clinical Oncology 27(26):4398-4405.

Ridley, D. 2009. Business of Drug Discovery. http://gspp.berkeley.edu/iths/RDStrategies/lecture4.ppt#425,1,Business of Drug Discovery (accessed August 3, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Ridley, R. G. 2002. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415(6872):686-693.

Ridley, R. G. 2003. Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnerships. EMBO Reports. Spec No: S43-46. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1326445/pdf/4-embor858.pdf (accessed August 3, 2010).

Rinaldi, A. 2005. Adopting an orphan. EMBO Reports 6(6):507-510.

Riordan J. R., J. M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066-1073.

Roach, J. C., G. Glusman, A. F. Smit, C. D. Huff, R. Hubley, P. T. Shannon, L. Rowen, et al. 2010. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science. http://www.sciencemag.org/cgi/rapidpdf/science.1186802v1.pdf (accessed August 3, 2010).

Roca, R. 2009. Summary review for regulatory action. Summary Review, Application Number 22-352 [Colcrys / colchicine]. July 30. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022352s000_SumR.pdf (accessed August 19, 2010).

Rockoff, R. D. 2010. An old gout drug gets new life and a new price, riling patients. Wall Street Journal, April 12. http://online.wsj.com/article/NA_WSJ_PUB:SB10001424052748703630404575053303739829726.html (accessed August 27, 2010).

Rosebraugh, C. 2010. Approval Letter to Auxilium Pharmaceuticals, Inc. for BLA 125338/0 [Xiaflex]. February 2. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/125338s000ltr.pdf (accessed August 20, 2010).

Rosecrans, H. 2010. Understanding the premarket notification (510(k)) process. Presentation at Public Health Effectiveness of the FDA 510(k) Clearance Process, Washington, DC. February 18.

Rosenberg, H., M. Davis, D. James, N. Pollock, and K. Stowell. 2007. Malignant hyperthermia. Orphanet Journal of Rare Diseases 2(1):21.

Rosenstein, B. J., and G. R. Cutting. 1998. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. Journal of Pediatrics 132(4):589-595.

Rubinstein, Y. R., S. C. Groft, R. Barteck, K. Brown, R. A. Christensen, E. Collier, A. Farber, et al. 2010. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemporary Clinical Trials 31(5):394-404.

SACGHS (Secretary’s Advisory Committee on Genetics, Health, and Society). 2008. U.S. System of Oversight of Genetic Testing. http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_oversight_report.pdf (accessed August 3, 2010).

Sands, S. 2010. IFib. Living with DMD. May 19. http://dmdpioneers.org/home/living-with-dmd/ifib (accessed August 20, 2010).

Sardiello, M. P., A. di Ronza, D. L. Medina, M. Valenza, V. A. Gennarino, C. D. Malta, F. Donaudy, et al. 2009. A gene network regulating lysosomal biogenesis and function. Science 325(5939):473-477.

Sasinowski, F. 2010. Statement of the National Organization for Rare Disorders (NORD) at the U.S. Food and Drug Administration Part 15 Public Hearing: Considerations Regarding FDA Review and Regulation of Articles for the Treatment of Rare Disease. Silver Spring, MD, June 29. http://www.rarediseases.org/files/NORD-statement-FDA-hearing-06-29-10.pdf (accessed August 3, 2010).

Sauer M., S. Grewal, and C. Peters. 2004. Hematopoietic stem cell transplantation for mucopolysaccharidoses and leukodystrophies. Klinische Pädiatrie 216:163-168.

Sawyers, C. L. 2010. Even better kinase inhibitors for chronic myeloid leukemia. New England Journal of Medicine 362:2314-2315.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Schact, W. H. 2007. The Bayh-Dole Act: Selected Issues in Patent Policy and the Commercialization of Technology. Congressional Research Service Report RL32076. http://fpc.state.gov/documents/organization/96463.pdf (accessed September 2, 2010).

Schact, W. H., and J. R. Thomas. 2009. Follow-on Biologics: Intellectual Property and Innovation Issues. Congressional Research Service Report RL33901. http://assets.opencrs.com/rpts/RL33901_20090803.pdf (accessed August 3, 2010).

Schadt, E. E., A. Sachs, and S. Friend. 2005a. Embracing complexity, inching closer to reality. Science Signaling 295:pe40.295:pe40.

Schadt, E. E., J. Lamb, X. Yang, J. Zhu, S. Edwards, D. Guhathakurta, S. K. Sieberts, et al. 2005b. An integrative genomics approach to infer causal associations between gene expression and disease. Nature Genetics 37(7):710-717.

Scheinberg, I. H., and J. M. Walshe. 1986.1986. Orphan Diseases and Orphan Drugs. Manchester, UK: Manchester University Press.

Schickedanz, A. D., and R. D. Herdman. 2009. Direct-to-consumer genetic testing: the need to get retail genomics right. Clinical Pharmacology and Therapeutics 86(1):17-20.

Schimke, R. N., D. L. Collins, and C. A. Stolle. 2009. Von Hippel-Lindau Syndrome. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=vhl#vhl.grID1694 (accessed August 3, 2010).

Schmitz, J., L. W. Poll, and S. vom Dahl. 2007. Therapy of adult Gaucher disease.Therapy of adult Gaucher disease. Haematologica 92(2):148-152.

Schofield, P. N., T. Bubela, T. Weaver, L. Portilla, S. D. Brown, J. M. Hancock, D. Einhorn, et al. 2009. Post-publication sharing of data and tools. Nature 461:171-173.

Schulte, F., and D. Donovan. 2007. Drug earning millions despite “orphan” label: Status granted before law increased use of “bupe.” Baltimore Sun.

Schultz, D. 2008. FDA public health notification: life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. FDA, Alerts and Notices (Medical Devices). July 1. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/UCM062000 (accessed August 12, 2010).

Scriver, C. R., and P. J. Lee. 2004. The last day of the past is the first day of the future: transitional care for genetic patients. American Journal of Medicine 117(8):615-617.

Scriver, C. R., and E. P. Treacy. 1999. Is there treatment for “genetic” disease? Molecular Genetics and Metabolism 68(2):93-102.

Segal, J. B., J. J. Strouse, M. C. Beach, C. Haywood, C. Witkop, H. Park, R. F. Wilson, et al. 2008. Evidence Report/Technology Assessment: Hydroxyurea for the Treatment of Sickle Cell Disease. AHRQ Publication No. 08-E007. http://www.ahrq.gov/downloads/pub/evidence/pdf/hydroxyurea/hydroxscd.pdf (accessed August 3, 2010).

Seoane-Vazquez, E., R. Rodriguez-Monguio, S. L. Szeinbach, and J. Visaria. 2008. Incentives for orphan drug research and development in the United States. Orphanet Journal of Rare Diseases 3(33). http://www.ojrd.com/content/pdf/1750-1172-3-33.pdf (accessed August 3, 2010).

Shah, R. R. 2006. Regulatory framework for the treatment of orphan diseases. In Fabry Disease: Perspectives from 5 Years of FOS, edited by A. Mehta, M. Beck, and G. Sunder-Plassmann. Oxford, UK: Oxford PharmaGenesis. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=fabry&part=A745 (accessed August 3, 2010).

Sing, C. F., J. H. Stengard, and S. L. R. Kardia. 2003. Genes, environment, and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 23(7):1190-1196.

Smith, V. K., K. Gifford, E. Ellis, R. Rudowitz, M. O. M. Watts, and C. Marks. 2009. The Crunch Continues: Medicaid Spending, Coverage and Policy in the Midst of a Recession. http://www.kff.org/medicaid/upload/7985.pdf (accessed August 3, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Smits, P., A. D. Bolton, V. Funari, M. Hong, E. D. Boyden, L. Lu, D. K. Manning, et al. 2010. Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210. New England Journal of Medicine 362(3):206-216.

So, A. D., and E. Stewart. 2009. Appendix F: Sharing knowledge for global health. In The U.S. Commitment to Global Health: Recommendations for the Public and Private Sectors. Institute of Medicine. Washington, DC: The National Academies Press. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=nap12642&part=a2001902dddd00191#a2001902dnnn00053 (accessed August 24, 2010).

Solomon, M. D., D. P. Goldman, G. F. Joyce, and J. J. Escarce. 2009. Cost sharing and the initiation of drug therapy for the chronically ill. Archives of Internal Medicine 169(8):740-748.

Sotos, J. G. 1989. Zebra Cards: An Aid to Obscure Diagnoses. Philadelphia, PA: American College of Physicians.

Sox, H. C. 2009. Evaluating off-label uses of anticancer drugs: time for a change. Annals of Internal Medicine 150(5):353-354.

Spiration, Inc. 2009. CMS Approves New Technology Add-on Payment for Spiration®IBV Valve System (press release). August 3. http://www.spiration.com/downloads/NTAPPressReleaseFinal.pdf (accessed August 3, 2010).

SSA (Social Security Administration). 2010a. Compassionate Allowances. http://www.social security.gov/compassionateallowances/ (accessed August 3, 2010).

SSA. 2010b. Medicare. http://www.ssa.gov/pubs/10043.pdf (accessed August 3, 2010).

Statistics Bureau (Japan). 2008. Statistical Handbook of Japan: Chapter 2 Population. http://www.stat.go.jp/english/data/handbook/c02cont.htm (accessed August 3, 2010).

Stein, R. 2010. FDA considers revoking approval of Avastin for advanced breast cancer. Washington Post, August 16. http://www.washingtonpost.com/wp-dyn/content/article/2010/08/15/AR2010081503466.html (accessed September 1, 2010).

Stein, S., M. G. Ott, S. Schultze-Strasser, A. Jauch, B. Burwinkel, A. Kinner, M. Schmidt, et al. 2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Medicine 16(2):198-204. E-pub January 24.

Steinberg, K. K., M. E. Cogswell, J. C. Chang, S. P. Caudill, G. M. McQuillan, B. A. Bowman, L. M. Grummer-Strawn, et al. 2001. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. Journal of the American Medical Association 285:2216-2222.

Steiner, R. 2009. Sitosterolemia. March 26. http://emedicine.medscape.com/article/948892-overview (accessed August 3, 2010).

Steiner R. D., S. L. Huhn, T. Koch, A. Al-Uzri, G. Guillaume, T. Sutcliffe, H. Vogel, and N. Selden. 2009. CNS transplantation of purified human neural stem cells in infantile and late-infantile neuronal ceroid lipofuscinoses: summary of the Phase I trial. Abstracts for the 11th International Congress of Inborn Errors of Metabolism. Molecular Genetics and Metabolism 98(1-2):76 (A422).

Stoffels, P. 2009. Collaborative innovation for the post-crisis world. Boston Globe, February 2. http://www.boston.com/bostonglobe/editorial_opinion/oped/articles/2009/02/02/collaborative_innovation_for_the_post_crisis_world?mode=PF (accessed August 3, 2010).

Stossel, T. P. 2008. The discovery of statins. Cell 134(6): 903-905. http://download.cell.com/pdf/PIIS0092867408011276.pdf?intermediate=true (accessed August 11, 2010).

Stratman, R. C., J. D. Flynn, and K. W. Hatton. 2009. Malignant hyperthermia: a pharmacogenetic disorder. Orthopedics 32:835.

Straube, B. M. 2009. Update: CMS and genetic applications in health care. Presentation to SACGHS Meeting, Washington, DC. March 12. http://oba.od.nih.gov/oba/SACGHS/meetings/March2009/Straube_slides.pdf (accessed August 3, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Sung, N. S., W. F. Crowley, Jr., M. Genel, P. Salber, L. Sandy, L. M. Sherwood, S. B. Johnson, et al. 2003. Central challenges facing the national clinical research enterprise. Journal of the American Medical Association 289(10):1278-1287.

Suthram, S., J. T. Dudley, A. P. Chiang, R. Chen, T. J. Hastie, and A. J. Butte. 2010. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Computational Biology 6(2): e1000662. http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000662 (accessed August 3, 2010).

Suzuki, M., K. Wlers, E. B. Brooks, K. D. Grels, K. Halnes, M. S. Klein-Gittleman, J. Olson, et al. 2009. Initial validation of a novel protein biomarker for active pediatric lupus nephritis. Pediatric Research 65(5):530-536.

Swann, J. P. 2003. The history of the FDA. In The Food and Drug Administration, edited by M. A. Hickman. Hauppauge, NY: Nova Science Publishers.

Swanson, J. 2009. Companion diagnostics take off. Genome Technology. http://www.genomeweb.com/dxpgx/companion-diagnostics-take (accessed August 3, 2010).

Tabor, H. K., and M. Bamshad. 2010. Exome sequencing and rare diseases. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4.

TDR (Special Programme for Research and Training in Tropical Diseases). 2008. BL3—drug discovery on fast track says expert advisors. TDRnews. May. http://apps.who.int/tdr/svc/publications/tdrnews/issue-80/drug-discovery-fast-track (accessed August 20, 2010).

Tejada, P. 2009. Towards an International Standard of Coding and Classification of Rare Diseases. http://archive.eurordis.org/imprimer.php3?id_article=2014 (accessed August 3, 2010).

Terry, S. F. 2009. Written statement for Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, U.S. House of Representatives, March 18. http://www.geneticalliance.org/statements.terry (accessed August 3, 2010).

Terry, S. F. 2010. Accelerate medical breakthroughs by ending disease earmarks. Nature Reviews Genetics 11:310-311.

Thaul, S. 2008. FDA Fast Track and Priority Review Programs. Congressional Research Service RS22814 (http://nationalaglawcenter.org/assets/crs/RS22814.pdf) (accessed August 27, 2010).

Therrell, B., F. Lorey, R. Eaton, D. Frazier, G. Hoffman, C. Boyle, D. Green, et al. 2008. Impact of expanded newborn screening. Morbidity and Mortality Weekly Report 57(37):1012-1015. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5737a2.htm (accessed August 3, 2010).

Thomson, G., N. Marthandan, J. A. Hollenbach, S. J. Mack, H. A. Erlich, R. M. Single, M. J. Waller, et al. 2010. Sequence feature variant type (sfvt) analysis of the hla genetic association in juvenile idiopathic arthritis. Pacific Symposium on Biocomputing 15:359-370.

Tillman, D. B. 2010. Approval letter for Medtronic Melody® Transcatheter Pulmonary Valve and Medtronic Ensemble® Transcatheter Valve Delivery System (H080002). January 25. http://www.accessdata.fda.gov/cdrh_docs/pdf8/H080002a.pdf (accessed August 19, 2010).

Tillman, D. B., and S. Gardner. 2004. Letter to Institute of Medicine committee on postmarket surveillance of pediatric medical devices, September 27. As cited in Safe Medical Devices for Children. 2006. Washington, DC: The National Academies Press.

Tollefson, L. 2008. Letter to Donald M. Poretz, President, Infectious Diseases Society of America Concerning the Orphan Drug Act, October 15. http://www.hivma.org/WorkArea/DownloadAsset.aspx?id=16139 (accessed August 24, 2010).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Torreele, E., M. Usdin, and P. Chirac. 2004. A needs-based pharmaceutical R&D agenda for neglected diseases. Paper prepared for the WHO Commission on Intellectual Property Rights, Innovation and Public Health. Version 31. July. http://www.who.int/intellectualproperty/topics/research/Needs%20based%20R&D%20for%20neglected%20diseases%20Els%20Pierre%20Martine.pdf (accessed September 7, 2010).

Trafton, A. 2010. Revolutionizing medicine one chip at a time. MIT News, March 9. Travis, J. 2008. Science by the masses. Science 319(5871):1750-1752.

Trikalinos, T. A., M. Chung, J. Lau, and S. Ip. 2009. Systematic review of screening for bilirubin encephalopathy in neonates. Pediatrics 124(4):1162-1171.

Tse, T., R. J. Williams, and D. A. Zarin. 2009. Reporting “basic results” in ClinicalTrials.gov. Chest 136(1):295-303.

Tufts Center for the Study of Drug Development. 2010. U.S. orphan product designations more than doubled from 2000-02 to 2006-08. Impact Report 12(1).

Ulatowski, T. 2009. Warning Letter to William Birdsall, Chief Executive Officer, MicroMed Technology, Inc. RE: DeBakey VAD Child. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm195995.htm (accessed August 19, 2010).

Unger, E. F., A. M. Thompson, M. J. Blank, and R. Temple. 2010. Erythropoiesis-stimulating agents—time for a reevaluation. New England Journal of Medicine 362(3):189-192.

UNOS (United Network for Organ Sharing). 2010. Financing a Transplant. http://www.transplantliving.org/beforethetransplant/finance/costs.aspx (accessed August 3, 2010).

U.S. Census Bureau. 2001. Monthly Estimates of the United States Population: April 1, 1980 to July 1, 1999, with Short-Term Projections to November 1, 2000. http://www.census.gov/population/estimates/nation/intfile1-1.txt (accessed August 3, 2010).

U.S. Census Bureau. 2009. Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2009 (NST-EST2009-01). Washington, DC. http://www.census.gov/popest/states/tables/NST-EST2009-01.xls (accessed August 3, 2010).

U.S. Congress, Senate Committee on Appropriations. 2008. Report on S. 1710 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Bill. Washington, DC.

UTHSCSA (University of Texas Health Science Center San Antonio). 2004. Titanium Rib Becomes 1st New FDA-Approved Spine Deformity Treatment in 40 Years (press release). http://www.uthscsa.edu/hscnews/singleformat2.asp?newID=1148 (accessed August 3, 2010).

Valeo, T. 2010. New molecule found to cross the blood-brain barrier: reported safe for patients with progressive glioma. Neurology Today 10(1):12-13. http://journals.lww.com/neurotodayonline/Fulltext/2010/01070/New_Molecule_Found_to_Cross_the_Blood_Brain.8.aspx (accessed August 3, 2010).

Van Eyk, J. E. 2010. Development of biomarkers. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4.

VCRC (Vasculitis Clinical Research Consortium). 2010. What Is the VCRC? http://rarediseasesnetwork.epi.usf.edu/vcrc/about/index.htm (accessed August 3, 2010).

Villa, S., A. Compagni, and M. R. Reich. 2008. Orphan drug legislation: lessons for neglected tropical diseases. International Journal of Health Planning and Management. http://www.wcfia.harvard.edu/sites/default/files/Reich_Orphan.pdf (accessed August 3, 2010).

Villarreal, M. A. 2001. Orphan Drug Act: Background and Proposed Legislation in the 107th Congress. Congressional Research Service Report RS20971. http://www.policyarchive.org/handle/10207/bitstreams/3490.pdf (accessed August 3, 2010).

Vodovotz, Y., M. Csete, J. Bartels, S. Chang, and G. An. 2008. Translational systems biology of inflammation. Public Library of Science Journal Computational Biology 4(4).

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Wade, N. 2010. Disease cause is pinpointed with genome. New York Times. http://www.nytimes.com/2010/03/11/health/research/11gene.html (accessed August 3, 2010).

Wagner, J. A., M. Prince, E. C. Wright, M. M. Ennis, J. Kochan, D. J. R. Nunez, B. Schneider, et al. 2010. The biomarkers consortium: practice and pitfalls of open-source precompetitive collaboration. Clinical Pharmacology and Therapeutics 87:539-542.

Walpoth, B. H., and G. L. Bowlin. 2005. The daunting quest for a small diameter vascular graft. Expert Review of Medical Devices 2(6):647-651.

Wang, D., T. Wood, M. Sadilek, C. R. Scott, F. Turecek, and M. H. Gelb. 2007. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clinical Chemistry 53:137-140.

Wang, S. S. 2010. Drug makers will share data from failed Alzheimer’s trials. Wall Street Journal, June 11. http://online.wsj.com/article/SB10001424052748703627704575298783153884208.html (accessed August 3, 2010).

Wasserstein, J. N., and K. R. Karst. 2007.2007. Orphan Drug Designation Not Sacrosanct—FDA Revokes Orphan Designation for TheraCLEC for EPI, but Other Exclusivity Issues Remain. July 11. http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2007/07/fda-revokes-alt.html (accessed August 3, 2010).

Watson, M. S., Marie Y. Mann, M. A. Lloyd-Puryear, P. Rinaldo, and R. R. Howell. 2006. Newborn screening: toward a uniform screening panel and system. Genetics in Medicine 8(5).

Waxman, H. J. Undated. Orphan Drugs. http://waxman.house.gov/IssueList/Internal/orphandrugs.htm (accessed August 3, 2010)

Wechsler, J. 2008. Orphan drug R&D challenges sponsors. Applied Clinical Trials. http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Articles/Orphan-Drug-RampD-Challenges-Sponsors/ArticleStandard/Article/detail/527733 (accessed August 3, 2010).

Weiss, K. D. 2005. Approval Letter to BioMarin Pharmaceutical, Incorporated for BLA 125117 [Galsulfase / Naglazyme]. May 31. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/125117_0000_ltr.pdf (accessed August 23, 2010).

Wellman-Labadie, O., and Y. Zhou. 2009. The U.S. Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95(2-3):216-228.

Wellmark Blue Cross Blue Shield. 2009. Humanitarian Use Devices: Medical Policy 10.01.14. http://www.wellmark.com/Provider/MedPoliciesAndAuthorizations/MedicalPolicies/Policies/Humanitarian_Use_Devices.aspx (accessed August 3, 2010).

Wellmark Blue Cross Blue Shield. 2010. Off-label Drug Use (Medical Policy). http://wwwprep.wellmark.com/Provider/MedPoliciesAndAuthorizations/MedicalPolicies/policies/_Off-label_Drug_UsePrinterFriendly.aspx (accessed August 3, 2010).

Whalen, J. 2009. Novartis shifts focus to rare diseases. Wall Street Journal, December 21.

WHO (World Health Organization). 2009a. Global Tuberculosis Control, Epidemiology. http://www.who.int/tb/publications/global_report/2009/pdf/chapter1.pdf (accessed August 3, 2010).

WHO. 2009b. Leishmaniasis: Burden of Disease. http://www.who.int/leishmaniasis/burden/en/ (accessed August 3, 2010).

Wolf, B. 2008. Biotinidase Deficiency [Late-Onset Biotin-Responsive Multiple Carboxylase Deficiency, Late-Onset Multiple Carboxylase Deficiency]. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=biotin (accessed August 3, 2010).

Wolfe, J. H. 2009. Gene therapy in large animal models of human genetic diseases. Institute for Laboratory Animal Research Journal 50(2):107-111.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

Wolfe, L. C. 2010. Chronic granulomatous disease: treatment and medication. eMedicine April 16. http://emedicine.medscape.com/article/956936-treatment (accessed August 11, 2010).

Wolff, A. C. 2009. The controversy: perspectives on HER2 testing for breast cancer. ASCO News & Forum. http://www.ascoconnection.org/LinkClick.aspx?fileticket=gN-fxKFh0xA%3d&tabid=78 (accessed August 3, 2010).

Wong, H. R., N. Cvijanovich, G. L. Allen, R. Lin, N. Anas, K. Meyer, R. J. Freishtat, et al. 2009. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Critical Care Medicine 37(5):1558-1566.

Wong, H. S., and H. Q. Wang. 2008. Constructing the gene regulation-level representation of microarray data for cancer classification. Journal of Biomedical Informatics 41(1):95-105. E-pub April 11, 2007.

Wood, A. J. J. 2006. A proposal for radical changes in the drug-approval process. New England Journal of Medicine 355(6):618-623.

Woodward, E. R., and E. R. Maher. 2006. Von Hippel-Lindau disease and endocrine tumor susceptibility. Endocrine-Related Cancer 13(2):415-425. http://www.ncbi.nlm.nih.gov/pubmed/16728571?dopt=Abstract (accessed August 20, 2010).

Woolf, S. H. 2008. The meaning of translational research and why it matters. Journal of the American Medical Association 299(2):211-213.

Yaplito-Lee, J., J. Pitt, J. Meijer, L. Zoetekouw, R. Meinsma, and A. B. van Kuilenburg. 2008. beta-Ureidopropionase deficiency presenting with congenital anomalies of the urogenital and colorectal systems. Molecular Genetics and Metabolism 93(2):190-194.

Yong, G., M. H. Salinger, and T. E. Feldman. 2007. Device closure for PFO: the data and devices associated with percutaneous PFO closure. Cardiac Interventions Today June:32-40.

Zacks, R. 2008. Artificial heart finally ready for market? Abiomed’s potential “billion-dollar monopoly.” xconomy, January 23. http://www.xconomy.com/2008/01/23/artificial-heart-finally-ready-for-market-abiomeds-potential-billion-dollar-monopoly/ (accessed August 3, 2010)

Zenios, S., J. Makower, P. Yock, T. J. Brinton, U. N. Kumar, L. Denend, and T. M. Krummel. 2010. Biodesign: The Process of Innovating Medical Technologies. New York: Cambridge University Press.

Zhang, F. R., W. Huang, S. M. Chen, L. D. Sun, H. Liu, Y. Li, Y. Cui, et al. 2009. Genomewide association study of leprosy. New England Journal of Medicine 361(27):2609-2618.

Zielinska, E. 2009. Team of rivals. TheScientist.com 23(11):62.

Zipes, D. P., P. Libby, R. O. Bonow, and E. Braunwald, eds. 2007. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8 ed. St. Louis, MO: W.B. Saunders.

Zlotogora, J. 2009. Population programs for the detection of couples at risk for severe monogenic genetic diseases. Human Genetics 126(2):247-253.

Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page249
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page250
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page251
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page252
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page253
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page254
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page255
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page256
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page257
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page258
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page259
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page260
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page261
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page262
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page263
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page264
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page265
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page266
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page267
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page268
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page269
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page270
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page271
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page272
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page273
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page274
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page275
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page276
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page277
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page278
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page279
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page280
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page281
Suggested Citation:"References." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page282
Next: Appendix A: Study Activities »
Rare Diseases and Orphan Products: Accelerating Research and Development Get This Book
×
Buy Paperback | $44.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!